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Abstract 
Siddheshwar J. Utge, a Study of Candidate Genes in Depression and Disturbed 
Sleep. National Institute for Health and Welfare (THL). Research 81/2012. 173 
pages. Helsinki, Finland 2012.  
ISBN 978-952-245-650-2 (printed); ISBN 978-952-245-651-9 (pdf)  
 
Depression is a complex psychiatric disorder that comprises a variety of symptoms, 
in addition to depressed mood state, including indications of disturbed sleep such as 
early morning awakenings and fatigue. Poor sleep has been demonstrated to be one 
of the modifiable risk factors in the onset of depression. Neurobiological and mo-
lecular genetic studies of depression and disturbed sleep have introduced a number 
of candidate genes; the mechanism of genetic vulnerability for depressive disorders 
remains largely unknown, however. In the present study, depressive patients were 
grouped according to the presence or absence of disturbed sleep (e.g., early morning 
awakenings and fatigue). The genetic background of depression was hypothesized to 
be different between these groups. The regulation of sleep, and of mood, was as-
sumed to partly share a common genetic background. The aim of this thesis was to 
identify genetic variants associated with depression and disturbed sleep in order to 
gain a better understanding of this hypothesis in the population-based Finnish sam-
ples.  
 
First, the association between genetic markers from 14 functionally-relevant candi-
date genes was assessed. These genes were related to serotonergic and glutamatergic 
neurotransmission, to neural plasticity, and to the hypothalamic-pituitary-adrenal 
axis (HPA-axis) with depression, depression with early morning awakenings, and 
depression with fatigue in a sample from the population-based Health 2000 survey 
(http://www.terveys2000.fi/indexe.html). Overall, 1654 individuals were studied 
(384 depressed patients and 1270 population-matched controls). The data suggested 
that allelic variants from a gene coding for a key regulatory protein of the serotoner-
gic neurotransmission system, namely tryptophan hydroxylase 2 (TPH2), is associ-
ated with depression accompanied by fatigue in females. An association between a 
number of genes related to glutamatergic neurotransmission and neural plasticity, 
such as glutamate decarboxylase 1 (GAD1), glutamate receptor, ionotropic, AMPA 
subunit 3 (GRIA3), and brain-derived neurotrophic factor (BDNF) with depression 
accompanied by fatigue in females. A significant association between cAMP re-
sponsive element binding protein 1 (CREB1), a neural plasticity related gene, and 
depression in men, was also identified. Of the genes related to the HPA-axis, an 
association was found between corticotropin releasing hormone receptor 1 (CRHR1) 
and depression accompanied by early morning awakenings in females. 
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The hypothesis was then expanded to encompass 18 genes from the circadian system 
in the same study subjects (N=1654) from the Health 2000 cohort. In this study, a 
significant association of two distinctive allelic variants of timeless homolog (Dro-
sophila) (TIMELESS) was associated with depression accompanied by fatigue (Per-
mutation-based corrected empirical P=0.0056), to seasonal mood fluctuation 
(Pointwise P=0.016) in females, and with depression accompanied by early morning 
awakenings (Permutation-based corrected empirical P=0.0374) in males. In an inde-
pendent set of 1512 control individuals (Genmets (D-) sample) from the complete 
Health 2000 cohort, the same  variant was also associated with seasonal mood fluc-
tuation (Pointwise P=0.036) in females, and with early morning awakenings (Point-
wise P=0.038) or fatigue (Pointwise P=0.0016) in healthy males.  
 
Finally, the shared genetic background for sleep and mood in healthy individuals 
(N=3147) drawn from the population-based Health 2000 and FINRISK study 2007 
survey (http://www.ktl.fi/portal/4168) was examined. In this study, for association 
analyses with sleep duration, 23 variants from 12 candidate genes were selected that 
had shown association (P<0.05) with depression and disturbed sleep in studies I and 
II. A significant association of a GRIA3 variation with sleep duration in females 
(Permutation-based corrected empirical P=0.00001) was identified. The frequency 
of the allele which associated with depression was highest among females who slept 
for 8 hours or less in all age groups younger than 70 years. However, no prominent 
associations were found among males, suggesting a sex-specific effect for the X-
chromosomal GRIA3 gene. 
  
In conclusion, these results support the involvement of genes, which are related to 
serotonergic (TPH2) or glutamatergic neurotransmission (GAD1, GRIA3), to neural 
plasticity (BDNF, CREB1), to the HPA-axis (CRHR1), and the circadian system 
(TIMELESS), in depression and disturbed sleep. The results obtained in this thesis 
support the hypothesis that the different phenotypes of depression and disturbed 
sleep would also be genetically distinct. The results indicate that depression is het-
erogeneous and that its genetic background may be partly different in women and 
men. This study also shows that the regulation of sleep and of mood may have 
common genetic backgrounds involving mechanisms of glutamatergic neurotrans-
mission. Additional studies are warranted to investigate these findings further. 
 
Keywords: depression, disturbed sleep, early morning awakenings, fatigue, candi-
date genes 
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Tiivistelmä 
Siddheshwar J. Utge, a Study of Candidate Genes in Depression and Disturbed 
Sleep. [Tutkimus kandidaattigeenit masennus ja unihäiriöt]. Terveyden ja hyvin-
voinnin laitos (THL). Tutkimus 81/2012, 173 sivua. Helsinki, Finland 2012. 
ISBN 978-952-245-650-2 (printed); ISBN 978-952-245-651-9 (pdf)   
 
Depressio on merkittävä psykiatrinen sairaus, johon kuuluu masentuneen mielialan 
lisäksi joukko muita oireita kuten unen häiriintymiseen liittyvät aamuyön heräilyt tai 
väsymys. Useat epidemiologiset tutkimukset osoittavat, että heikko uni on yksi mer-
kittävimmistä depression riskitekijöistä.  Jaottelimme tutkimuksessamme potilaat 
sen mukaan, ilmenikö heillä unen häiriöihin liittyviä oireita. Hypoteesinamme oli, 
että geneettinen depressioalttius olisi ainakin osin erilainen riippuen siitä, ilmeneekö 
potilaalla häiriintyneeseen uneen liittyviä oireita. Toinen tutkimushypoteesimme oli, 
että unen ja mielialan geneettisessä säätelyssä on ainakin osin yhteneväisiä meka-
nismeja. 
 
Selvitimme aluksi toiminnallisten, serotoniini- tai glutamiinihermovälitykseen, plas-
tisuuteen ja stressinsäätelyyn liityvien ehdokasgeenien assosiaatiota (i) depressioon, 
(ii) depressioon ja aamuyön heräilyyn ja (iii) depressioon ja väsymykseen väestö-
pohjaisessa Terveys 2000-aineistossa. Tuloksemme osoittivat että osa geeneistä, 
kuten serotoniinin tuottoa aivoissa säätelevä TPH2, liittyy depressioon naisilla sil-
loin kun oireena on myös väsymystä. Lisäksi havaitsimme naisilla useiden eri glu-
tamiinivälitykseen sekä plastisuuteen liittyvien geenien assosiaation depressioon ja 
väsymykseen ja stressinsäätelyjärjestelmän CRHR1-geenin assosiaation depressioon 
ja aamuyön heräämisiin. Miehillä totesimme depression merkittävän assosiaation 
CREB1 – geeniin. 
  
Laajensimme tutkimuksemme vuorokausirytmiä sääteleviin ns. kellogeeneihin. Ha-
vaitsimme kahden eri TIMELESS-geenimuodon assosioituvan depressioon ja väsy-
mykseen sekä depressioon ja aamuyön heräämiseen miehillä. Samat riskivariantit 
asioituivat myös terveillä naisilla mielialan vuodenaikaiseen vaihteluun ja miehillä 
aamuyön heräilyihin. 
 
Tutkimme myös depression ja mielialan geneettistä taustaa selvittämällä aiemmin 
tunnistamiemme riskivarianttien vaikutusta unen pituuteen terveillä, Terveys 2000 – 
ja Finriski 2007 – aineistoista poimituilla yksilöillä. Tunnistimme glutamiiniresepto-
ria koodaavan GRIA3-geenin variaation assosiaation unen pituuteen. Sama alleeli, 
joka assosioitui naisilla depressioon, assosioitui terveillä naisilla lyhyeen yöuneen. 
  
Tuloksemme osoittavat, kuinka serotoniini- (TPH2) ja glutamiinihermovälitykseen 
(GAD1, GRIA3), plastisuuteen (CREB1), HPA-akselin toimintaan (CRHR1) tai sir-
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kadiaaniseen systeemiin (TIMELESS) liittyvillä geeneillä on tehtävä depression ja 
häiriintyneen unen etiologiassa. Tuloksemme viittaavat siihen, että depression etio-
logia olisi ainakin osittain erilainen riippuen potilaan oirekuvasta etenkin unen häiri-
ön suhteen. Tuloksemme osoittavat myös depression heterogeenisyyden ja sen, että 
sairauden geneettinen etiologia on ainakin osittain erilainen naisilla ja miehillä. Li-
säksi löydöksemme antavat viitettä siitä, että unen ja mielialan geneettinen säätely 
sisältävät päällekkäisiä, mm. glutamiinihermovälitykseen liittyviä mekanismeja. 
Jatkotutkimuksia tarvitaan, jotta voisimme ymmärtää näitä mekanismeja paremmin. 
  
Avainsanat: depressioon, depressioon ja aamuyön heräilyyn, depressioon ja väsy-
mykseen väestöpohjaisessa 
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1 INTRODUCTION 
Depression is a severe mood disorder, a common condition, and leading cause of 
morbidity and disability, affecting about 121 million people worldwide. Depression 
affects 6-7% of the population annually and 16% of people during their lifetime 
(Kessler et al., 2003, Pirkola et al., 2005). A recent study on a representative sample 
of the Finnish population (Health 2000) shows that depressive disorder is more 
common in women than in men; the respective 12-month prevalence rates are 8.3% 
and 4.6% (Pirkola et al., 2005). According to twin studies, the heritability of major 
depressive disorder (MDD) is clearly higher in women (42%) than in men (29%), 
and some genetic risk factors are suggested to be involved (Kendler et al., 2006). 
Recently, similar gender related findings were obtained for life dissatisfaction, de-
pressed mood, and depressive disorder in a sample of 18,631 same-sex Finnish 
twins, with additive heritability estimates up to 53% in females and 39% in males 
(Paunio et al., 2009). 
  
Sleep problems are common in depression; about 90% of depressed individuals 
suffer from sleep difficulties (Tsuno et al., 2005). People with depression have char-
acteristic changes in their sleep architecture and show typically a poor quality of 
sleep, have trouble falling asleep, awaken frequently during the night, and also 
awaken very early in the morning with difficulties to get back to sleep (Benca et al., 
1997, Nofzinger et al., 2004). As a consequence, they feel very tired or lacking in 
energy (fatigue) during the daytime (Benca et al., 1997, Nofzinger et al., 2004). 
Dysregulation of circadian rhythms also contributes to depressive episodes and to 
sleep disruption (McClung, 2007). Depression and disturbed sleep are complex 
processes, which involve various biological and psychological processes. The pre-
sent study focuses on the correlation of genetic susceptibility factors, to depression 
with signs of disturbed sleep, such as early morning awakenings and fatigue. 
 
The Human Genome Project (HGP) and the Human Haplotype Map Project (Hap-
Map) have offered effective tools for the identification of genetic risk factors for 
etiologically multifactorial diseases. The work presented in this thesis explores ge-
netic contributions to depression, and how they actually contribute to sleep variabil-
ity. In this study, a candidate gene approach has been utilized to elucidate the 
genetic background of depression and disturbed sleep in Finnish population-based 
samples. 
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2 REVIEW OF THE LITERATURE 
2.1 Overview of major depressive disorder 
2.1.1 Diagnosis 
 
Depression is characterized by depressed mood, accompanied by changes in think-
ing, feeling, behavior, and physical well-being. MDD consists of one or more major 
depressive episodes (MDE) lasting for two weeks with the symptoms presented in 
table 1 (American Psychiatric Association, 2000). According to the American Psy-
chiatric Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV-TR), the diagnosis of MDD requires at least five (or more) different symptoms, 
out of a list of nine, of which two are fatigue (or loss of energy) and insomnia (or 
hypersomnia). The patient’s state represents a change from the individual’s normal 
mood and performance. The symptoms must include depressed mood or a consistent 
loss of interest or pleasure in daily activities. A depressed mood due to the sub-
stances of drug abuse, to a medication or other treatment, or a general medical con-
dition, is not considered to be MDD. 
REVIEW OF THE LITERATURE 
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Table 1. Diagnostic criteria for major depressive episode as outlined in the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (American 
Psychiatric Association, 2000). 
 
A. Five of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning: at least one of the symp-
toms is either 1) or 2). 
1) Depressed mood most of the day, nearly every day 
2) Markedly diminished interest or pleasure in all, or almost all activities most of 
the day, nearly every day 
3) Significant weight loss while not dieting, or weight gain, or decrease or increase 
in appetite nearly every day 
4) Insomnia or hypersomnia nearly every day 
5) Psychomotor agitation or retardation nearly every day 
6) Fatigue or loss of energy nearly every day 
7) Feelings of worthlessness or excessive or inappropriate guilt nearly every day 
8) Diminished ability to think or concentrate or indecisiveness nearly every day 
9) Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, 
or a suicide attempt or a specific plan for committing suicide 
B. The symptoms do not meet criteria for a mixed episode. 
C. The symptoms cause clinically significant distress or impairment in social, oc-
cupational or other important areas of functioning. 
D. The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition. 
E. The symptoms are not better accounted for by bereavement. 
 
According to the DSM-IV-TR, dysthymia presents a chronic form of depression in 
which depressed mood is nearly constantly present for at least two years, accompa-
nied by at least two (or more) of the other listed symptoms (Table 2) (American 
Psychiatric Association, 2000). 
REVIEW OF THE LITERATURE 
 
THL — Research 81/2012 20 A Study of Candidate Genes in Depression and Disturbed Sleep 
 
Table 2. Diagnostic criteria for dysthymia as outlined in the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV-TR) (American Psychiatric 
Association, 2000). 
 
A. Depressed mood for most of the day, for more days than not, as indicated either 
by subjective account or observation by others, for at least 2 years. 
B. Presence, while depressed, of two of the following: 
1) Poor appetite or overeating 
2) Insomnia or hypersomnia 
3) Low energy or fatigue 
4) Low self-esteem 
5) Poor concentration or difficulty making decisions 
6) Feelings of hopelessness 
C. During the 2-year period of the disturbance, the person has never been without 
the symptoms of criteria A and B for more than 2 months at a time. 
D. No major depressive episode has been present during the first 2 years of the 
disturbance; i.e., the disturbance is not better accounted for by chronic major de-
pressive disorder, or major depressive disorder, in partial remission. 
E. There has never been a manic episode, a mixed episode or a hypomanic episode, 
and criteria have never been met for cyclothymic disorder. 
F. The disturbance does not occur exclusively during the course of a chronic psy-
chotic disorder, such as schizophrenia or delusional disorder. 
G. The symptoms are not due to the direct physiological effects of a substance or a 
general medical condition. 
H. The symptoms cause clinically significant distress or impairment in social, oc-
cupational or other important areas of functioning. 
 
 
2.1.2 Epidemiology 
2.1.2.1 Depression 
 
Depression is anticipated to become a leading cause of disability worldwide by the 
year 2020 (Murray and Lopez, 1997). Epidemiological studies indicate that depres-
sion is highly prevalent in all populations (Kessler et al., 1994, Kessler et al., 2003, 
Jacobi et al., 2004), but the estimates vary according to populations and studies. 
Prevalence is an epidemiological measure in public health; it is divided into point 
prevalence and period prevalence. The point prevalence is the percentage of people 
in a given population which suffer from a disorder or a specified condition at a point 
REVIEW OF THE LITERATURE 
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in time. The period prevalence is the percentage of people having the condition dur-
ing a given period of time, or a year (Streiner et al., 2009). Lifetime prevalence is 
the percentage of people in a given population up to the time of assessment who 
have had the diagnosis of the disorder at some point in their life (Streiner et al., 
2009). 
 
The lifetime prevalence of MDD is 10-25% for females and 5-12% for males 
(American Psychiatric Association, 2000). The point prevalence of developing 
MDD at any given point in time is 5-9% for females and 2-3% for males (American 
Psychiatric Association, 2000). The prevalence rate of MDD varies worldwide, be-
tween an estimated life time prevalence of 3% in Japan, to 16.9% in the United 
States (Andrade et al., 2003). Differences in these figures can arise, in principal, 
from differences in sampling, in populations and their racial/ethnic groups, from the 
diagnostic tools used, or from changes in prevalence over time within populations 
(Blazer et al., 1994, Lindeman et al., 2000). The various estimates for lifetime, point 
or period prevalence of major depression worldwide are summarized in table 3. 
Epidemiological studies on the general population show that the lifetime prevalence 
of dysthymia is 3-6% (Akiskal, 1994, Serretti et al., 1999, Avrichir and Elkis, 2002). 
In the Finnish population, a 6-month prevalence of dysthymia was reported as 2% 
(Isometsa et al., 1997) and the 12-month prevalence in the Health 2000 survey over-
all was 2.5% (3% for females and 1.9% for males) (Pirkola et al., 2005). 
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Table 3. Epidemiological surveys on major depressive episode. 
Country 
(Study) 
Diagnostic 
criteria 
Prevalence 
(%) 
Lifetime 
prevalence 
(%) 
N Reference 
Australia 
(NSMHWB) 
CIDI  
(DSM-IV) 
6.3 *** n.s. 10641 (Andrews et al., 
2001) 
Australia 
(NSMHWB) 
CIDI  
(DSM-IV) 
3.2* n.s. 10641 (Wilhelm et al., 
2003) 
Belgium 
(ESMeD) 
CIDI  
(DSM-IV) 
5.0*** 14.1 2419 (Bromet et al., 2011) 
Brazil 
(ICPE) 
WHO-CIDI 
(DSM-III-R) 
3.9* 
5.8*** 
12.6 1464 (Andrade et al., 
2003) 
Brazil 
(Sao Paulo) 
CIDI  
(DSM-IV) 
10.4*** 18.4 5037 (Bromet et al., 2011) 
Canada  
(ICPE) 
UM-CIDI 
(DSM-III-R) 
1.9* 
4.3*** 
8.3 6902 (Andrade et al., 
2003) 
Canada 
(CCHS1.2) 
WMH-CIDI 
(DSM-IV) 
1.8* 12.2 36984 (Patten et al., 2006) 
Chile 
(ICPE) 
CIDI 
(DSM-III-R) 
3.3*  
5.6*** 
9.0 2978 (Andrade et al., 
2003) 
China 
(Shenzhen) 
CIDI  
(DSM-IV) 
3.8*** 6.5 7132 (Bromet et al., 2011) 
Colombia 
(NSMH) 
CIDI  
(DSM-IV) 
6.2*** 13.3 4426 (Bromet et al., 2011) 
Czech Republic 
(ICPE) 
CIDI 
(DSM-IV) 
1.0* 
2.0*** 
7.8 1534 (Andrade et al., 
2003) 
Europe 
(DEPRES) 
MINI 
(DSM-III) 
6.9** n.s. 13359 (Lepine et al., 1997) 
Finland 
(FINHCS) 
UM-CIDI  
(DSM-III-R) 
9.3*** n.s. 5993 (Lindeman et al., 
2000) 
Finland UM-CIDI  
(DSM-III-R) 
4.1** n.s. 2293 (Isometsa et al., 
1997) 
Finland 
(Health 2000) 
M-CIDI 
(DSM-IV) 
4.9*** n.s. 6005 (Pirkola et al., 2005) 
France 
(ESMeD) 
CIDI  
(DSM-IV) 
5.9*** 21.0 2894 (Bromet et al., 2011) 
Germany 
(ICPE) 
M-CIDI 
(DSM-IV) 
1.3* 
5.2*** 
11.5 3021 (Andrade et al., 
2003) 
Germany 
(ESMeD) 
CIDI  
(DSM-IV) 
3.0*** 9.9 3555 (Bromet et al., 2011) 
India 
(WMHI) 
CIDI  
(DSM-IV) 
4.5*** 9.0 2992 (Bromet et al., 2011) 
Israel 
(NHS) 
CIDI  
(DSM-IV) 
6.1*** 10.2 4859 (Bromet et al., 2011) 
Italy 
(ESMeD) 
CIDI  
(DSM-IV) 
3.0*** 9.9 4712 (Bromet et al., 2011) 
Japan 
(ICPE) 
UM-CIDI 
(DSM-III-R) 
0.9* 
1.2*** 
3.0 1029 (Andrade et al., 
2003) 
Japan 
WMHJ 
CIDI  
(DSM-IV) 
2.2*** 6.6 3416 (Bromet et al., 2011) 
Korea 
(Seoul) 
DSM-III 2.3*** 2.9 5100 (Weissman et al., 
1996) 
Lebanon 
(LEBANON) 
CIDI  
(DSM-IV) 
5.5*** 10.9 2857 (Bromet et al., 2011) 
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Mexico 
(ICPE) 
UM-CIDI 
(DSM-III-R) 
2.2* 
4.5*** 
8.1 1734 (Andrade et al., 
2003) 
Mexico 
(M-NCS) 
CIDI 
(DSM-IV) 
4.0*** 
 
8.0 
 
5782 (Bromet et al., 2011) 
Netherlands 
(NEMESIS) 
CIDI  
(DSM-III-R) 
2.7* 
5.8*** 
15.4 7076 (Bijl et al., 1998) 
Netherlands 
(ICPE) 
WHO-CIDI 
(DSM-III-R) 
2.7*  
5.9*** 
15.7 7076 (Andrade et al., 
2003) 
Netherlands 
(ESMeD) 
CIDI  
(DSM-IV) 
4.9*** 17.9 2372 (Bromet et al., 2011) 
New Zealand DSM-III 5.8*** 11.6 1498 (Weissman et al., 
1996) 
New Zealand 
(NZMHS) 
CIDI  
(DSM-IV) 
6.6*** 17.8 12790 (Bromet et al., 2011) 
Puerto Rico DSM-III 3.0*** 4.3 1513 (Weissman et al., 
1996) 
Spain 
(ESMeD) 
CIDI  
(DSM-IV) 
4.0*** 10.6 5473 (Bromet et al., 2011) 
South Africa 
(SASH) 
CIDI  
(DSM-IV) 
4.9*** 9.8 4315 (Bromet et al., 2011) 
Taiwan DSM-III 0.8*** 1.5 11004 (Weissman et al., 
1996) 
Turkey 
(ICPE) 
WHO-CIDI 
(DSM-III-R) 
3.1* 
3.5*** 
6.3 6095 (Andrade et al., 
2003) 
Ukraine 
(CMDPSD) 
CIDI  
(DSM-IV) 
8.4*** 14.6 4724 (Bromet et al., 2011) 
United States 
(ICPE)   
UM-CIDI 
(DSM-III-R) 
4.6* 
10.0*** 
16.9 5877 (Andrade et al., 
2003) 
United States  
(NCS-R) 
CIDI  
(DSM-IV) 
6.6*** 16.2 9090 (Kessler et al., 2003) 
United States  
(NCS-R) 
CIDI  
(DSM-IV) 
8.3*** 19.2 9282 (Bromet et al., 2011) 
N-Sample size,*point prevalence (a month or less), **6-month prevalence, ***12 month 
prevalence, n.s.-not specified. NSMHWB (National Survey of Mental Health and Well-
being); ESMeD (The European Study of The Epidemiology of Mental Disorders); ICPE 
(International Consortium of Psychiatric Epidemiology); CCHS1.2 (The Canadian 
Community Health Survey: Mental Health and Well-Being); NSMH (The Colombian 
National Study of Mental Health); DEPRES (Depression Research in European Society); 
FINHCS (Finnish Health Care Survey); WMHI (World Mental Health India); NHS (Is-
rael National Health Survey); WMHJ (World Mental Health Japan Survey); LEBANON 
(Lebanese Evaluation of the Burden of Ailments and Needs of the Nation); M-NCS 
(Mexican National Comorbidity Survey); NEMESIS (Netherlands Mental Health Survey 
and Incidence Study); NZMHS (New Zealand Mental Health Survey); SASH (South 
Africa Stress and Health Study); CMDPSD (Comorbid Mental Disorders during Periods 
of Social Disruption); NCS-R (National Comorbidity Survey Replication); UM-CIDI 
University of Michigan version of the Composite International Diagnostic Interview. 
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2.1.2.2  Sleep disturbances and depression 
 
Most individuals suffering from depression experience disturbances, such as insom-
nia (Doghramji, 2003). In fact 90% of depressed individuals are reported to have 
sleep difficulties (Benca et al., 1997, Tsuno et al., 2005). Insomnia is a perception of 
insufficient sleep, and it affects approximately 9% to 12% of the population 
(Mellinger et al., 1985, Ford and Kamerow, 1989, Taylor et al., 2005). The lifetime 
prevalence of major depression has been reported to be 31.1% in individuals with a 
history of insomnia, 25.3% in those with hypersomnia, 54.3% in those with insom-
nia and hypersomnia,  and 2.7% in those with no history of sleep disturbances 
(Breslau et al., 1996).  
Fatigue is one of the key symptoms of disturbed sleep in depression. The lifetime 
prevalence of depression among those with fatigue is 20.7% (Addington et al., 
2001), whereas individuals without a history of fatigue reported a 2.3% lifetime 
prevalence for depression (Addington et al., 2001). Results of a cross-sectional 
study of depression in primary-care patients demonstrate that complaints of sleep 
disturbances and fatigue had the greatest predictive values (61% and 60%, respec-
tively) for significant depressive symptoms (Gerber et al., 1992). These epidemiol-
ogical findings show that the individuals with sleep disturbances have an increased 
prevalence of major depression. 
2.1.3  Etiology and candidate genes 
Depression comprises a heterogeneous group of disorders (Kendler et al., 1993). 
The etiology of depression includes psychological, physiological, and environmental 
factors (Bebbington, 1999, Manji et al., 2001, Caspi et al., 2003, Kendler et al., 
2004), as summarized in figure 1. 
 
 
Figure 1. Etiological factors considered to contribute to depression. 
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Neurotransmitters  
 
Neurotransmitters are chemical messengers which conduct signals from one nerve 
cell to another. They play a central role in the pathophysiology of brain disorders, 
thus are targets for pharmacological treatments. Among the various neurotransmit-
ters and their roles, the present thesis is focusing on the monoamines, particularly 
serotonin, amino acids (glutamate), and neuropeptide neurotransmitters (corticotro-
pin releasing hormone), which will be discussed in more detail in the following 
sections. 
 
Monoamines 
It has been hypothesized, that reduced levels of monoamines at the synapse underlie 
depression or mood disorders (Castren, 2005). This theory is supported by the clini-
cal finding that monoamine re-uptake inhibitors, which increase the neurotransmitter 
level in the synaptic cleft, alleviate the symptoms of depression (Castren, 2005). 
 
Serotonin. Serotonin is synthesized from tryptophan. In the human body, most sero-
tonin is found in the enterochromaffin cells of the digestive tract where it regulates 
intestinal movements (Reid and Rand, 1952). In the brain, most serotonergic neu-
rons are located in the raphe nuclei (Figure 2) (Berger et al., 2009).  
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Figure 2. Serotonin and dopamine pathways in the brain. A serotonergic pathway 
(red) arises from neurons in the monoaminergic cell groups, including the dorsal and 
median raphe nuclei which are grouped together in the brainstem (Saper et al., 2005). A 
dopaminergic pathway (blue) arises from neurons in the monoaminergic cell groups, 
including the substantia nigra and ventral tegmental areas (VTA) which are located in 
the midbrain (Stahl and Mignon, 2010).   
Elevated or decreased levels of serotonin in the brain may also cause drastic changes 
in behavior (Saper et al., 2005), and this neurotransmitter system has accordingly 
been widely investigated in the pathophysiology of depression, or psychiatric disor-
ders (Manji et al., 2001). Many components of the serotonergic system, such as 
serotonin-1a receptor (5-HT1A), serotonin-2a receptor (5-HT2A) and serotonin trans-
porter (5-HTT), are associated with the neurobiology of mood and act as mediators 
for the therapeutic actions of antidepressants (Rajkumar and Mahesh, 2008).  
 
A low cerebrospinal fluid (CSF) level of the serotonin metabolite 5-
hydroxyindolacetic acid (5-HIAA) is associated with depression (Placidi et al., 
2001). In vivo imaging studies of depressed patients and controls show differences 
in the binding of 5-HTT in the regions that receive dense serotonergic projections 
from the midbrain raphe nuclei. Lower 5-HTT binding in the amygdala and mid-
brain region in patients with major depression has been found in positron emission 
tomography (PET) studies (Parsey et al., 2006, Oquendo et al., 2007). These find-
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ings indicate that the function of 5-HTT contributes to the pathogenesis of depres-
sion.  
 
Catecholamines. The family of catecholamines includes adrenaline (A) (epineph-
rine), noradrenaline (NA) (norepinephrine), and dopamine, all synthesized from 
tyrosine. In the CSF, the concentration of NA has been reported to be low in de-
pressed patients (Post et al., 1978), while in some studies it has been reported to be 
higher in the plasma of depressed patients (Esler et al., 1982, Rothschild et al., 1987, 
Kelly, 2004). However, not all studies report elevated plasma levels (Rudorfer et al., 
1985, Healy et al., 1992). Dopamine is synthesized in cell groups of the substantia 
nigra and the VTA in the midbrain (Figure 2). Dysfunction in dopaminergic neuro-
transmission has been suggested in the pathophysiology of depression, since dopa-
mine metabolites have been measured in the plasma of depressed patients. Several 
studies consequently reported that the plasma levels of the dopamine metabolite 
(HVA) were lower in depressed patients (Mitani et al., 2006a). In contrast, suicide 
victims without a history of depression have normal levels of HVA, dopamine, and 
NA, based on the results of some autopsy studies (Pare et al., 1969, Beskow et al., 
1976). 
 
Several genes and proteins are involved in the regulation of the monoaminergic 
pathways (Figure 3). Genetically determined alterations in their activity may thus 
have a role in the vulnerability for depression. The present thesis focused on the 
candidate genes summarized in table 4. 
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Figure 3.  Schematic overview of serotonin and dopamine neurotransmission. Neu-
rotransmission consists of several steps, including: 1) synthesis of neurotransmitters, 2) 
storage in synaptic vesicles, 3) release into the synaptic cleft upon depolarization of the 
neuron, 4) binding to postsynaptic receptors or binding to autoreceptors located on the 
presynaptic membrane, 5) reuptake from the synaptic cleft after depolarization 
(Mohammad-Zadeh et al., 2008). Panel A) The synthesis, storage, release, and uptake of 
serotonin via the selective serotonin transporter (5-HTTLPR variant of SERT/SLC6A4), 
and its metabolism via MAO-B. Panel B) The synthesis and metabolism of dopamine 
(Catecholamine). Dopamine is metabolized by monoamine oxidase-A (MAO-A) to 3, 4-
dihydroxyphenylacetic acid (DOPAC). DOPAC diffuses out of the presynapse and trans-
formed to homovanillic acid (HVA) in the presence of catechol-O-methyltransferase 
(COMT) (Westerink, 1985, Mannisto et al., 1992). COMT is located outside the dopa-
minergic neurons. A fraction of the released dopamine is metabolized to 3-
methoxytyramine (3-MT), then oxidized in the presence of MAO-A to HVA (Westerink, 
1985, Mannisto et al., 1992). TPH=Tryptophan hydroxylase, AAD=Amino acid decar-
boxylase, MAO-B=monoamine oxidase-B, 5-HIAA=5-hydroxyindoleacetic acid. 
TH=Tyrosine hydroxylase, L-DOPA=levodopa. 
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Table 4. Candidate genes involved in the regulation of serotonin and catecholamine. 
Gene Name Function Chromosome Reference in 
depression 
TPH2 Tryptophan  
hydroxylase 2 
Rate-limiting 
enzymes in-
volved in the 
biosynthesis of 
serotonin 
12q21 
 
(Zill et al., 
2004a) 
MAOA Monoamine  
oxidase A 
Degrades amine 
neurotransmitters 
Xp11.3 
 
(Schulze et 
al., 2000) 
SLC6A4 Solute carrier fami-
ly 6 (neurotransmit-
ter transporter, 
serotonin),  
member 4 
Serotonin  
transporter 
17q11-q12 (Ogilvie et 
al., 1996) 
COMT catechol-O-
methyltransferase  
Role in the 
breakdown of 
dopamine in 
brain 
22q11.21  (Massat et 
al., 2005) 
 
 
Tryptophan hydroxylase (TPH) is the rate-limiting enzyme for the synthesis of sero-
tonin (Figure 3). TPH determines the amount of serotonin available in the brain. 
Therefore, it is regarded as a candidate gene for the pathogenesis of depression. It 
has two isoforms, TPH1 and TPH2 (Mockus and Vrana, 1998).  TPH1 gene is lo-
cated on chromosome 11p15.3–p16 and TPH2 on chromosome 12q21, spans a re-
gion of 29 kb and 93.5 kb, respectively. Both are highly homologous and share 71% 
of their amino-acids (Walther and Bader, 2003). TPH2 is a brain-specific isoform, 
and acts as rate-limiting enzyme in the synthesis of serotonin in neural tissue 
(Walther and Bader, 2003). The peripheral biosynthesis of serotonin is initiated by 
TPH1 (Walther and Bader, 2003). Studies on human and rodent tissues confirmed 
that TPH1 is predominantly expressed in the enterochromaffin cells of the gut and in 
lower amounts in the pineal gland (Brain) (Sakowski et al., 2006). TPH2 is not ex-
pressed in peripheral organs (liver, kidney, heart or lung), but mainly expressed in 
the neurons of the raphe nuclei in the brain stem, and in peripheral myenteric neu-
rons in the gut (Matthes et al., 2010). Several genetic studies have reported an asso-
ciation with single nucleotide polymorphisms (SNPs) in TPH2 and depressive disor-
der (Zill et al., 2004a, Zhang et al., 2005, Zhou et al., 2005, Van Den Bogaert et al., 
2006, Haghighi et al., 2008, Tsai et al., 2009), or with suicide in MDD (Zill et al., 
2004b, Ke et al., 2006, Lopez de Lara et al., 2007). 
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Monoamine oxidase (MAO) is a mitochondrial outer membrane-bound enzyme 
involved in the degradation of serotonin and dopamine (Figure 3). MAO exists in 
two forms: MAO-A and MAO-B. Both the genes encoding the MAOs are located on 
the X-chromosome and are homologous; they share 60% identity (Zhu et al., 1992). 
In the CNS, MAO-A is found in the catecholaminergic neurons (Lewis et al., 2007), 
while MAO-B is highly expressed in the serotonergic neurons, and astrocytes (Chen, 
2004). MAO enzymes preferentially degrade serotonin, catecholamines by oxidative 
deamination (Shih and Thompson, 1999), an ability which made these enzymes 
candidates for the study of neurological diseases, and of psychiatric and behavioural 
phenotypes. There is variable number tandem repeat (VNTR) functional polymor-
phism in the promoter region of MAO-A gene. This polymorphic sequence consists 
of a 30-bp repeated sequence (MAO-A-30 bp VNTR) as 2, 3, 3.5, 4 or 5 repeats (R) 
and has been shown to affect the transcriptional activity of the MAO-A promoter 
(Sabol et al., 1998). The alleles with (3.5R or 4R) of the repeat sequence are tran-
scribed more efficiently than those with (3R or 5R) copies of the repeat (Sabol et al., 
1998). Therefore, the alleles with 3.5R or 4R are related to higher central MAO-A 
activity and to lower central serotonin level (Sabol et al., 1998). An association 
study of this functional polymorphism showed the frequency of the 4R allele signifi-
cantly increased in MDD patients (Yu et al., 2005). 
 
The serotonin transporter gene 5-HTT (SLC6A4) is located on the chromosome 
17q11.2, spanning a 38 kb region. The variation (5-HTT -linked polymorphic region, 
5-HTTLPR) at the promoter region of SLC6A4 modulates the transcriptional activity 
of the gene. The 5-HTTLPR consists of two common alleles, a 44-bp insertion or 16 
imperfect repeats of an approximately 22-base-pair element (long or L allele), and a 
deletion or allele with 14 repeats (short or S allele) located exactly at the 5’-flanking 
regulatory region (Heils et al., 1996). The S allele of 5-HTTLPR relate to signifi-
cantly less mRNA and protein, resulting in a lower concentration of serotonin in the 
synaptic cleft, than the L variant (Lesch et al., 1996). The S allele of 5-HTTLPR is 
associated with increased risk for depression in the presence of stressful life events, 
such as childhood maltreatment (Caspi et al., 2003). The promoter sequence within 
the 5-HTTLPR region also includes a single nucleotide polymorphism (SNP) 
rs25531 (A→G substitution) (Nakamura et al., 2000), where the G allele diminishes 
SLC6A4 transcription efficiency (Hu et al., 2006). Other polymorphic regions in the 
serotonin transporter include a 17 bp variable number of tandem repeats in the sec-
ond intron (intron 2 VNTR or STin2 VNTR) which also modulates the transcription 
of SLC6A4 (Hranilovic et al., 2004). Genetic variation in the serotonin transporter 
gene (5-HTTLPR, rs25531) associated with an increased risk for MDD (Holmes et 
al., 2010). 
 
The catechol-o-methyltransferase (COMT) gene is located on the chromosome 
22q11.21, spanning a 27.2 kb region. The enzyme catechol-o-methyltransferase 
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degrades catecholamines and helps to maintain their level in the brain. The most 
widely studied variation within the COMT gene is the Val108/158Met polymor-
phism (rs4680) which changes the amino acid valine to methionine at position 108 
of the shorter form of the enzyme or at position 158 of the longer form (Williams et 
al., 2007). This variation within the COMT gene is associated with various mental 
illnesses (Craddock et al., 2006).  
 
 
 
Amino acids (Glutamate) 
Glutamate is the excitatory amino acid neurotransmitter which is ubiquitously dis-
tributed in mammalian brain tissue (Fonnum, 1984). There is growing evidence that 
dysregulation of glutamate occurs in patients with MDD (Mitchell and Baker, 2009). 
Increased glutamate levels were measured in the plasma of depressed patients 
(Mauri et al., 1998, Mitani et al., 2006b). The CSF level of glutamate in patients 
with MDD was also significantly higher than in controls (Levine et al., 2000). Post-
mortem studies have shown that brain glutamate levels were elevated in the frontal 
cortex tissues of depressed patients (Hashimoto et al., 2007, Feyissa et al., 2010), 
whilst a magnetic resonance spectroscopy (MRS) study in patients with MDD re-
vealed increased levels of glutamate in the occipital cortex (Sanacora et al., 2004). 
Autopsy studies showed lower mRNA levels of glutamate receptors (NMDA, 
AMPA and kinate) in tissue samples from the prefrontal cortex of patients with 
MDD (Beneyto et al., 2007, Feyissa et al., 2009). In addition, to date, evidence has 
emerged that glutamatergic receptors have antidepressant-like activity (Paul and 
Skolnick, 2003). 
 
Several proteins and genes are involved in glutamatergic neurotransmission. The 
present study addresses the following candidate genes (Figure 4; Table 5) which 
have, in previous studies, shown to be involved in the etiology of neuropsychiatric 
disorders. 
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Figure 4.  Schematic overview of glutamate synthesis and metabolism. In the brain, 
glutamate is generated as a by-product of energy metabolism and plays a role in all 
known brain functions. The metabolism of glutamate involves both neurons and 
astroglial cells. In astroglial cells, the γ-Aminobutyric acid (GABA) and glutamate are 
metabolized to glutamine and recycled to neurons to form glutamate or GABA (Palmada 
and Centelles, 1998). Released adenosine triphosphate (ATP), coenzyme in astroglial 
cells enters into the glutamatergic presynapse via purinergic receptor P2X, ligand-gated 
ion channel, 7 (P2RX7) (Illes and Ribeiro, 2004). ATP promotes calcium ion (Ca++) 
influx into the presynaptic terminal and leads to the release of glutamate from the 
presynaptic neurons (Burnstock, 2008). Released glutamate binds to N-methyl-D-
aspartate (NMDA) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors or kainate receptors (Mitchell and Baker, 2009). The normal function 
of D-serine in the brain is to activate the NMDA receptor (Chumakov et al., 2002).  
GABA is an inhibitory neurotransmitter, synthesized from glutamate with the help of the 
enzyme glutamic acid decarboxylase (GAD). The excess amount of glutamate, GABA 
and ATP is taken up by surrounding astroglial cells. GRIA1=glutamate receptor, 
ionotropic, AMPA subunit 1, GRIA2=glutamate receptor, ionotropic, AMPA subunit 2, 
GRIA3=glutamate receptor, ionotropic, AMPA subunit 3. 
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Table 5. Candidate genes involved in the regulation of glutamate. 
Gene Name Function Chromosome Reference in 
depression 
DAOA  
(G72) 
D-amino acid oxida-
se activator 
Glutamate 
signaling 
13q33 
 
(McGuffin et al., 
2005, Rietschel et 
al., 2008) 
GAD1 Glutamate  
decarboxylase 1 
Catalyzes 
production of 
GABA 
2q31.1 
 
(Hettema et al., 
2006) 
GRIA3 Glutamate receptor, 
ionotropic, AMPA 
subunit 3 
Glutamate 
receptor 
Xq25 (Laje et al., 2007) 
P2RX7 Purinergic receptor 
P2X, ligand-gated 
ion channel, 7  
ATP binding, 
ion channel 
activity 
12q24  (Lucae et al., 
2006) 
 
D-amino acid oxidase activator (DAOA) (or named G72) is located on chromosome 
13q33, spanning a 65 kb region. The G72 protein activates the enzyme D-amino 
acid oxidase (DAAO), which oxidizes D-serine (Boks et al., 2007) (Figure 4), and 
consequently attenuates glutamatergic neurotransmission at NMDA receptors (Hall 
et al., 2008). The genetic marker from G72 is found to be associated with bipolar 
disorder, schizophrenia (SCZ), and depression (Hall et al., 2008, Soronen et al., 
2008, Rietschel et al., 2008). 
 
Glutamate decarboxylase (GAD), is the rate-limiting enzyme in the conversion of 
glutamate to GABA in the mammalian brain (Harrison, 2007). The activation of 
GABA (A) receptors favors sleep (Gottesmann, 2002). GAD has two isoforms, GAD1 
and GAD2 (Fehr et al., 2003), located on chromosomes 2q31.1 and 10p11.23, span-
ning 45 kb and 79 kb genomic regions, respectively (Bu and Tobin, 1994). The genes 
GAD1 and GAD2 encode proteins with molecular weights of 65 kDa (GAD65) and 67 
kDa (GAD67), which are coexpressed in GABAergic neurons. A postmortem brain 
study showed a reduction in the levels of GAD proteins in the cerebellum of patients 
with schizophrenia, bipolar disorder, and major depression (Fatemi et al., 2005).  
 
The glutamate receptor, ionotropic, AMPA subunit 3 (GRIA3) is one of the four 
AMPA receptor subunits. GRIA3 gene is located on chromosome Xq25, spanning a 
300 kb genomic region, and mediates the signaling of excitatory neurotransmission in 
the brain (Gecz et al., 1999). GRIA3 is expressed in the reticular nucleus of the thala-
mus and the cortex (Beneyto and Meador-Woodruff, 2004), which are important areas 
in the regulation of sleep and wakefulness (McCormick and Bal, 1997, Steriade, 2006). 
 
The purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7), a gene coding 
for a purinergic ligand-gated ion channel, belongs to the P2RX receptor family. 
P2RX7 is located on the chromosome 12q24, spanning a 250 kb region. This gene is 
activated by an increased level of extracellular ATP (Surprenant et al., 1996) (Figure 
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4), and has a role in learning and memory responses, and in mood disorders 
(Burnstock, 2008, Soronen et al., 2011). 
 
 
Neuroplasticity 
In the biological sciences, the term plasticity refers to the capability of cells or organ-
isms to change their phenotypes in response to their environment (Skipper et al., 
2010). It specifically refers to the ability of neurons to acquire information based on 
outside experiences and make the appropriate responses by strengthening or weaken-
ing nerve connections (synapses), or by adding new nerve cells and forming new syn-
aptic connections to compensate for injury (Rao et al., 1999, Rioult-Pedotti and 
Donoghue, 2003). Neuroplasticity is involved in encoding information during learning 
and memory storage (Duman et al., 2000). There are several studies indicating that 
impairment of neuroplasticity may be involved in the development of many neuropsy-
chiatric diseases (Teter and Ashford, 2002, Frost et al., 2004, Castren, 2005).  
 
Patients with major depression exhibit memory problems, such as a diminished ability 
to think or to concentrate. Hippocampal activity is essential for cognitive functions 
(Zakzanis et al., 1998). An experimental animal study showed that chronic or severe 
stress can disrupt hippocampus-dependent memory (Diamond et al., 1999). Stress-
induced deficits in hippocampus-dependent memory formation are observed in de-
pression (Pittenger and Duman, 2008). Depressed patients show a volume loss in their 
hippocampus, possibly due to glutamate neurotoxicity-induced tissue loss, stress-
induced reduction in neurotrophic factors or stress-induced reduction in neurogenesis 
(Sheline, 2000). Hippocampal synaptic strength is modified by long-term potentation 
(LTP) and long term depression (LTD) (Malenka and Bear, 2004). In animal models 
of depression it has been found that chronic, mild stress can impair hippocampal LTP 
(Alfarez et al., 2003) and enhance LTD (Holderbach et al., 2007). Furthermore, chan-
ges in a process, which includes cell proliferation, differentiation and migration (neu-
rogenesis), are linked to the pathophysiology of MDD (Kempermann and Kronenberg, 
2003, Nissen et al., 2010). Animal models of depression showed decreased neuro-
genesis (Alonso et al., 2004, Holderbach et al., 2007) and an increase in newborn 
neurons upon treatment with antidepressants (Malberg et al., 2000). 
 
At the structural level, synaptic plasticity can occur either at the pre or the post syn-
apse (Figure 5). The genes and proteins, which are involved in the cellular mecha-
nism of plasticity, are many. The present study focused on four candidate genes, 
which were shown to be involved in the etiology of depression (Figure 5; Table 6). 
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Figure 5. Schematic overview of the molecular pathways involved in neural plasticity 
[Figure modified from  (Pittenger and Duman, 2008)]. Neuroplasticity is triggered by 
conductance of calcium ions (Ca++) into the synaptic terminal. The local elevations in Ca++ 
increases cAMP postsynaptically, which leads to an activation of protein kinase A (PKA) and 
calcium-calmodulin-dependent kinase (CaMK) signaling. A mitogen-activated protein kinase 
(MAPK) signal transduction pathway is also involved in the plasticity. The MAPK cascade is 
triggered by an activation of neurotrophic tyrosine kinase, receptor (TRKB), on the binding 
of brain-derived neurotrophic factor (BDNF). Upon sufficient elevation of PKA, CaMK, and 
MAPK, signal transduction cascades transmit signals to the nucleus where the transcription 
factor, cAMP responsive element binding protein (CREB), which is involved in the regula-
tion of synaptic change, is activated. These pathways are influenced by chronic stress and 
depression, have been associated with reductions in the transcription factor CREB (Pittenger 
and Duman, 2008). The cAMP–CREB cascade is up-regulated by antidepressant treatment 
(Manji et al., 2001, Castren, 2005). NMDA-R=N-methyl-D-aspartate glutamate receptor, 
AMPA-R=amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid glutamate receptor, 
PDE4=phosphodiesterase 4, DISC1=disrupted in schizophrenia 1. 
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Table 6. Candidate genes involved in the regulation of neuroplasticity. 
Gene Name Function Chromosome Reference in 
depression 
DISC-1 Disrupted in 
schizophrenia-1 
Neurodeve-
lopment and 
neural  
signaling 
1q42 (Hashimoto et 
al., 2006) 
BDNF Brain-derived 
neurotrophic 
factor 
Plasticity 
 
11p13 (Sen et al., 2003, 
Schumacher et 
al., 2005) 
NTRK2 
(TRKB) 
Neurotrophic 
tyrosine kinase, 
receptor, type 2  
Receptor for 
BDNF 
 
9q22.1 
 
(Dong et al., 
2009) 
CREB1 cAMP responsi-
ve element bin-
ding protein 1 
Transcription 
factor 
2q33.3 
 
(Zubenko et al., 
2003, Perlis et 
al., 2007, Dong 
et al., 2009) 
 
The schizophrenia-1 gene (DISC-1) is located on chromosome 1q42 and spans a 415 
kb region. It is highly expressed in the hippocampus and the cerebral cortex 
(Schurov et al., 2004). Functionally, DISC-1 is involved in neurodevelopment and 
synaptic modulation (Schurov et al., 2004). DISC-1 has been implicated in the regu-
lation of cAMP signaling through interaction with PDE4, and it coordinates PKA-
mediated signaling, which has a role in cell migration (Pawson and Scott, 2010). 
The carriers of the Cys704  allele of a genetic variant (Ser704Cys, rs821616) of the 
DISC-1 gene, showed reduced gray matter volumes, linked to lower extracellular 
signal-regulated kinase activity,  which has been suggested to have a role in the 
pathophysiology of MDD (Hashimoto et al., 2006). Mutations in DISC-1 are also 
associated with SCZ and BP (Hennah et al., 2003, Palo et al., 2007).  
 
Brain-derived neurotrophic factor (BDNF) is a protein that belongs to the neurotro-
phin (nerve growth factor-related proteins) superfamily. The BDNF protein is coded 
by the BDNF gene, spanning a 67 kb region on chromosome 11p13. The physiologi-
cal role of BDNF in the developing and adult CNS is to promote, modify, develop, 
and support the survival of neurons (Castren and Rantamaki, 2010). BDNF signaling 
is involved in neurogenesis, neuronal plasticity, and also in the pathophysiology in 
MDD (Castren, 2005). The serum level of BDNF is reduced in depressed patients, 
while antidepressant treatment can normalize the level (Castren and Rantamaki, 
2010).  
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The neurotrophic tyrosine kinase receptor type 2 (NTRK2), also called TRKB, is a 
tyrosine protein kinase, which is encoded by the NTRK2 gene. It is located on chro-
mosome 9q22.1, spanning a 350 kb region. It mediates the plasticity-enhancing 
effects of BDNF (Castren and Rantamaki, 2010). Postmortem brain studies have 
revealed a reduction in hippocampal TRKB and BDNF mRNA levels in suicide 
victims with depression (Kohli et al., 2010).  
 
The CREB1 gene encodes the cyclic AMP responsive element binding protein 1, 
located on chromosome 2q33.3, spanning a 69 kb region. CREB functions as a tran-
scription factor and plays an important role in the regulation of cellular responses 
involved in the development and survival of neuronal cells, and in neuronal differen-
tiation and memory formation (Lonze and Ginty, 2002). Increase in the level of 
calcium or cAMP in a synapse triggers the phosphorylation and activation of CREB. 
The CREB gene codes for three alternatively spliced activators α, β, and Δ (Silva et 
al., 1998). CREB α, β, mutant mice demonstrate a significant increase in hippocam-
pal neurogenesis, compared to wild-type mice, and they respond to acute antidepres-
sant treatment (Gur et al., 2007). In humans, sequence variations in the promoter 
and in intron 8 of CREB1 have been found to be associated with mood disorders 
(Zubenko et al., 2003).  
 
HPA-axis 
The hypothalamic-pituitary-adrenal axis (HPA-axis) is a complex functional system 
related to the regulation of stress and involving interaction between the hypothala-
mus, the pituitary gland and the adrenal gland. The HPA-axis plays an important 
role in the regulation of stress, sexuality, mood, sleep, and energy or fatigue (Hafez 
and Hafez, 2004, Buckley and Schatzberg, 2005, Gottschalk et al., 2005, Holsboer 
and Ising, 2010). A stress response, triggers the release of corticotropin-releasing 
factor/hormone (CRF/CRH) from the hypothalamus, which activates CRH receptor 
1 (CRHR1) in the pituitary gland, leading to the secretion of adrenocorticotropic 
hormone (ACTH) to the circulation. ACTH then travels to the adrenal glands, where 
it activates the secretion of glucocorticoids (cortisol, a stress hormone, in humans, 
and corticosterone in rodents). Cortisol then binds to corticosteroid receptors in the 
hypothalamus and the anterior pituitary, to inhibit further synthesis and release of 
CRF from the hypothalamus in a negative-feedback loop (de Kloet et al., 2005). 
Dysfunction of corticosteroid receptors (glucocorticoid receptor (GR)) may lead to 
hyperactivity of the HPA-axis (Buckley and Schatzberg, 2005). HPA-axis hyperac-
tivity is associated with sleep disturbances (Buckley and Schatzberg, 2005). An 
elevated cortisol level also associates with stress related disorders (Feder et al., 
2009), major depression (Keller et al., 2006), as well as with sleep disturbances 
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associated depression (Arborelius et al., 1999). Of the genes from the HPA-axis, 
NR3C1 and the CRHR1 were focused on here (Table 7), as they have been shown 
previously to be involved in depression.  
 
Table 7. Candidate genes involved in the regulation of HPA-axis. 
Gene Name Function Chromosome Reference in 
depression 
NR3C1 Nuclear recep-
tor subfamily 3, 
group C,  
member 1 
Glucocorticoid 
receptor  
 
5q31.3  
  
(van West et al., 
2006) 
CRHR1 Corticotropin-
releasing hor-
mone receptor 1  
Corticotropin-
releasing fac-
tor/hormone 
(CRF/CRH) 
 receptor 
17q12-q22 
  
(Liu et al., 2006, 
Bradley et al., 
2008, Wasser-
man et al., 2009) 
 
The glucocorticoid receptor (GR) is encoded by the nuclear receptor subfamily 3, 
group C, member 1 gene (NR3C1), which is located on chromosome 5q31.3 span-
ning a 157.58 kb region. It plays an important role in maintaining homeostasis after 
stress and in regulating nervous and immune system functions (Jokinen et al., 2007). 
In the brain, GR modulates cognition, addiction, and emotional behavior (Tronche et 
al., 1999). Various studies have suggested an impaired function, or decreased ex-
pression, of GR in patients with depression, for example, postmortem studies have 
revealed reduced GR levels in the hippocampus and in several other brain areas of 
patients with depression (Lopez et al., 1998, Webster et al., 2002). 
 
The corticotropin-releasing-hormone receptor 1 gene (CRHR1), on chromosome 
17q21-22 spanning a 20 kb region, encodes a G-protein coupled receptor. CRHR1 is 
expressed in the pituitary gland, where it mediates the action of CRF (Liu et al., 
2006). Genetic variants of the CRHR1 gene are associated with depression (Liu et 
al., 2006, Bradley et al., 2008, Wasserman et al., 2009). 
 
2.1.4 Genetic background 
 
Heritability of depression. Heritability is defined as ‘the proportion of phenotypic 
variance attributable to genetic variance’ (Falconer, 1989). Heritability estimates for 
MDD range from 17% to 78% (Sullivan et al., 2000). Both genetic and environ-
mental risk factors are involved in the etiology of the disease (Kendler et al., 1995, 
Caspi et al., 2003, Farmer et al., 2005). Stressful life events and traumatic childhood 
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events, such as abuse, often precipitate an onset of MDD (Williamson et al., 1998, 
Caspi et al., 2003). Genetic variations also modify the susceptibility to stressful life 
experiences and thereby the onset of MDD (Kendler et al., 1995, Caspi et al., 2003). 
A candidate gene study on a functional polymorphism (5-HTTLPR) in the upstream 
regulatory region of the serotonin transporter gene (SLC6A4) revealed an association 
with the onset of depression in the presence of life stress (Caspi et al., 2003). The 
homozygote carriers of the S allele (SS) of 5-HTTLPR showed more depressive 
symptoms, MDD diagnoses, and suicidality in relation to stressful life events than 
those homozygous for the L allele (LL) (P<0.001) (Caspi et al., 2003). A recent 
meta-analysis on studies published up to 2006 also reported a significant association 
between the 5-HTTLPR alleles (S vs. L) and MDD (Odds ratio (OR) for S al-
lele=1.11) (Lopez-Leon et al., 2008). However, this report did not include any in-
formation on gene-environment (GxE) interaction (Lopez-Leon et al., 2008). An-
other meta-analysis study of GxE interaction found that 5-HTTLPR genotypes (SS, 
SL, or LL), alone or in interaction with stressful life experiences, were not associ-
ated with increased risk of depression, either in men or women (Risch et al., 2009). 
Furthermore, a meta-analysis exploring the GxE interaction, up to 2009, supports the 
hypothesis that 5-HTTLPR moderates the relationship between stress and depression 
(Karg et al., 2011). Therefore, some authors suggest that 5-HTTLPR may not di-
rectly associate with MDD but modulate the effect of serotonin on stress (Uher and 
McGuffin, 2008). However, the discrepant findings of GxE may originate from 
differences in methodology, definitions of the phenotype, or the quality of environ-
mental exposure measurements (Caspi et al., 2010). 
 
Gender. Depressive disorder is more prevalent in women than in men (Kessler et al., 
1993, Bebbington, 1996, Kuehner, 2003) which raises the possibility that some gen-
der-related factors could play a role in MDD. The ratio of depression prevalence 
female/male is 2:1 (Jennet, 1977). The heritability estimate for MDD in women was 
42%, and in men 29%, according to a twin study (Kendler et al., 2006). A twin 
study showed that females without a history of depression and who had experienced 
stressful life events, such as divorce or a death of a loved one, had an increased risk 
for developing depression (by 6%) (Kendler et al., 2000). On the other hand, those 
with a history of family depression were 14% more likely to develop depression 
(Kendler et al., 2000). The higher rate of depression in women may be due to 
stresses from adolescence emotions, and reproductive events (Ruderman and 
O’Campo, 1999). Similarly, a study of female mice has shown that the expression of 
serotonin transporter gene was influenced through transcriptional modification by 
sex hormones (Gubbels Bupp et al., 2008). During stressful events, there is a lower 
rate of serotonin synthesis in females making them more susceptible to MDD than 
men (Nishizawa et al., 1997). This may be further compounded in both women and 
men by a functional polymorphism (5-HTTLPR) in the serotonin transporter gene 
(SLC6A4) that can also modulate the effect of serotonin on stress (Kendler et al., 
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1995, Caspi et al., 2003). Moreover, corticotropin-releasing factor (CRF), a media-
tor of the stress response, is dysregulated in stress-related psychiatric disorders 
(Bangasser et al., 2010). During stress, CRF activates the locus ceruleus (LC), the 
source of the brain norepinephrine system that regulates emotional arousal 
(Bangasser et al., 2010). There is evidence for estrogen regulation of CRF gene 
expression, interaction with neurotransmitter systems that can induce sex-specific 
changes in mood (Dzaja et al., 2005, Bangasser et al., 2010). Hence, gender differ-
ences between females and males are most likely a combination of biological, envi-
ronmental, and psychological factors. 
 
2.2  Sleep 
 
Sleep is a behavioral state characterized by reclined position, closed eyes, decreased 
movement, and decreased responsiveness to the internal and external environment 
(Markov and Goldman, 2006), as well as specific timing in the day as part of the 
circadian sleep-wake activity cycle (Zee and Vitiello, 2009). 
 
Sleep disturbances. Disturbed sleep is characterized by difficulties to fall asleep, 
waking up during the night, early morning awakenings, waking up feeling unre-
freshed, fatigue (tiredness, feeling of weariness, or lack of energy), and day time 
sleepiness (Grandner and Kripke, 2004). The disturbed sleep observed in depressed 
patients usually includes decreased sleep efficiency ( a ratio of amount of time spent 
in bed/total sleep time) and sleep duration (Kupfer and Reynolds, 1992). One 
polysomnographic study showed 85% sleep efficacy in healthy controls and 72% in 
depressed patients (Leistedt et al., 2009). Depressed patients also suffer from de-
creased slow wave sleep (SWS), increased REM sleep, and disturbances in sleep 
continuity (Srinivasan et al., 2009). Disturbed sleep patterns, like short or prolonged 
sleep duration and insomnia, are associated with an increased risk to mental and 
physical health. To sleep less than 6 hours per night is a risk factor for acute myo-
cardial infarction, hypertension, and coronary heart disease (Liu and Tanaka, 2002, 
Ayas et al., 2003, Gangwisch et al., 2006). Short (<6 hours per night) and long sleep 
(>8 hours per night) can both predispose to developing diabetes (Chaput et al., 
2009) and also depression (Perlman et al., 2006). Sleep disturbances in depression 
have been suggested to originate from disturbances in the neurotransmitter system, 
as well as disturbances in the circadian system, which is also involved in the regula-
tion of sleep (Armitage, 2007). 
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2.2.1 Regulation of sleep 
 
According to a widely accepted sleep regulation model, there are two biological 
factors which regulate sleep. Factor 1 is a sleep-wake dependent homeostatic com-
ponent (Process S), and factor 2 is a sleep-wake independent circadian component 
(Process C). The interaction of these two factors is described by the two process 
sleep regulation model (Borbely, 1982) (Figure 6). 
 
 
 
Figure 6. The two process model of sleep regulation [Figure modified from 
(Borbely and Achermann, 1999)]. The graphical representation of the upper curve 
displays the homeostatic (Process-S) and the lower curve the circadian rhythm cycle 
(Process-C), the x-axis indicates time of day, the dark black bar indicates the times 
where sleep normally occurs. Process-S indicates sleep propensity, the accumulated 
sleep pressure which increases during waking and declines during sleep. Sleep occurs 
when Process-S is at its peak and Process-C is declining. 
2.2.1.1 Sleep homeostasis (Process-S) 
 
The homeostatic regulation of sleep can be explained as a consequence of the accu-
mulation of some substance during waking. Process-S is controlled by various inter-
acting neural systems in the brain such as the hypothalamus, basal forebrain (BF), 
and brainstem nuclei (Borbely, 1982, Espana and Scammell, 2004). It has been sug-
gested that wakefulness, through consumption of brain energy resources, results in a 
depletion of brain energy, more specifically a depletion of brain glycogen stores 
(Benington and Heller, 1995). Adenosine is the end-product of the break-down of 
ATP, being a signal of energy shortage. The extracellular levels of adenosine in-
crease during prolonged wakefulness in the BF of both cats and rats (Porkka-
Heiskanen et al., 1997, Basheer et al., 1999). Adenosine promotes sleep through 
adenosine A1 (A1R) or A2A receptors. Injection of an A1R receptor agonist into the 
BF area in rats (Basheer et al., 1999), or of A2A receptor agonist into the subarach-
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noidal space, increases sleep (Satoh et al., 1998). It has been proposed that the in-
crease in extracellular adenosine concentration during waking could inhibit the ac-
tivity of cholinergic cells, which act as wakefulness promoting cell groups in the BF 
(Porkka-Heiskanen, 1999). Inhibition of the wake-promoting cells induces sleep, 
and during sleep the extracellular adenosine concentrations decrease and waking 
becomes possible again (Porkka-Heiskanen, 1999). 
 
2.2.1.2 Circadian system (Process-C) 
 
The circadian rhythm consists of the rhythmic activity of various physiological 
processes over a period of approximately 24 hours. It controls many biological and 
physiological processes in the body, including the sleep-wake cycle, digestive and 
hormonal activity, cell proliferation, and body temperature (Stratmann and Schibler, 
2006). The master biological clock is located in the suprachiasmatic nucleus (SCN) 
of the anterior hypothalamus (Hastings, 1998). The SCN synchronizes the circadian 
oscillators of neuronal cells, as well as peripheral cells, as far as they are not light 
sensitive (Schibler et al., 2003). If the SCN is lesioned, the rhythms become desyn-
chronized and can function with different periods (Edgar et al., 1993). The SCN is 
situated above the optic chiasm (Ibata et al., 1999, Abrahamson and Moore, 2001). 
Light stimulation to the SCN is mediated through the retino-hypothalamic tract 
(RHT), which originates from retinal ganglion cells which contain the light sensitive 
photopigment molecule melanopsin (Berson et al., 2002). In addition to light signals, 
the SCN also receives nonphotic input via serotonergic projections from the mid-
brain raphe nuclei and also from the retinorecipient subcortical nuclei such as the 
ventral lateral geniculate nucleus (vLGN) and the intergeniculate leaflet (IGL) 
(Harrington, 1997, Turek, 1998). Furthermore, the light signal passes on through the 
SCN to the pineal gland, which synthesizes and releases melatonin (Moore and Lenn, 
1972, Richardson, 2005). Melatonin secretion increases in darkness while light 
evokes an immediate decrease (Ueyama et al., 1999). The intrinsic circadian period 
in humans is slightly longer than 24 hours (Wulff et al., 2009). Therefore, the cir-
cadian system needs a daily synchronization (entrainment) of the endogenous oscil-
lator to the solar day (Wulff et al., 2009). The activation of SCN neurons by direct 
neural input from the retina via the RHT adjusts the biological clock to work in 
phase with the 24 h light-dark cycle (Moore and Lenn, 1972). The circadian system 
provides wake stimulus and counteracts the accumulating homeostatic sleep pres-
sure during waking hours (Edgar et al., 1993). 
 
Overall, in the ‘regulation of sleep’, Process-C determines the timing of sleep 
whereas Process-S maintains the intensity and duration of sleep (Wulff et al., 2009).  
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2.2.1.3 Genetic regulation 
 
Circadian genes behind the regulation of sleep and depression. Genes involved in 
the generation of circadian rhythms (~24-hour cycles) are called clock genes. The 
light-dark cycle stimulates molecular events in the circadian clock (Bunney and 
Bunney, 2000). Various biological clock components act as transcriptional activa-
tors or repressors, generating feedback loops of the core circadian genes which 
maintain endogenous clock rhythms. The aryl hydrocarbon receptor nuclear translo-
cator-like protein (ARNTL, alias BMAL1) and the clock homolog protein (CLOCK, 
alias bHLHe8) genes are the core components (Figure 7).  
 
 
 
Figure 7. Schematic presentation of clock gene transcriptional/translational feed-
back loops in the SCN of mammals [Figure modified from (Fu and Lee, 2003)].  At 
the begning of the circadian day, in response to light, ARNTL expression levels are high 
whereas CLOCK remains steady (Fu and Lee, 2003). The high activity level of ARNTL 
in the nucleus promotes the formation of a heterodimer complex of ARNTL with either 
CLOCK or NPAS2 (alias bHLHe9) (not shown in figure). Once formed, this complex 
binds to E-box elements in the promoter of three period genes (PER1, PER2 and PER3) 
and two cryptochrome genes (CRY1 and CRY2), as well as to other feedback loops in-
cluding the transcription factors orphan nuclear receptors, REV-ERBα and RORα gene 
(alias RORA), thereby activating their transcription (Hastings et al., 2003). After tran-
scription and translation, negative feedback is achieved by the PER and CRY heterodi-
mer complex, REV-ERBα, and RORα (Not shown in figure) proteins, which translocate 
back to the nucleus from the cytoplasm to suppress their own expression by inhibiting 
the ARNTL and CLOCK complex (Kume et al., 1999). Late in the subjective day, a 
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post-translational modification takes place for the accumulated PER and CRY proteins 
in the cytoplasm (Hastings et al., 2003). The casein kinase 1, epsilon (CKIε) phosphory-
lates PER proteins whereas unstable forms are degraded. The CRY proteins promote the 
formation of stable PER/ CKIε /CRY complexes that enter the nucleus during night time, 
where they inhibit the ARNTL, PER, CRY and REV-ERBα transcription (Preitner et al., 
2002). The interacting feedback loop ensures that at the beginning of a new circadian 
day, the levels of PER and CRY are low (Fu and Lee, 2003). A number of other core 
clock genes (not shown in figure) (Table 13), such BHLHE41 (alias DEC2), TIMELESS, 
TIPIN, NFIL3, BHLHE40, NR1D1, DBP, are directly or indirectly participating in the 
work of molecular clock. ARNTL=aryl hydrocarbon receptor nuclear translocator-like 
protein, CLOCK=clock homolog protein, NPAS2=neuronal PAS domain protein 2, 
PER1=Period homolog 1 (Drosophila), PER2=Period homolog 2 (Drosophila), 
PER3=Period homolog 3 (Drosophila), CRY1=Cryptochrome 1 (photolyase-like), 
CRY2=Cryptochrome 2 (photolyase-like), REV-ERBα=Nuclear receptor subfamily 1, 
group D, member 1, RORA=RAR-related orphan receptor A, CSNK1E (alias 
CKIε)=casein kinases-1 epsilon, BHLHE41=basic helix-loop-helix family, member e41, 
TIMELESS=timeless homolog (Drosophila), TIPIN=TIMELESS interacting protein, 
NFIL3=nuclear factor, interleukin 3 regulated, BHLHE40=basic helix-loop-helix family, 
member e40, NR1D1=nuclear receptor subfamily1, group D, member1, DBP=D site of 
albumin promoter (albumin D-box) binding protein. 
 
A disruption of circadian oscillators can trigger sleep abnormalities and mood disorders 
in humans. For instance, in familial advanced sleep phase syndrome (FASPS), a mis-
sense mutation within the CKIε binding region of PER2 causes hypophosphorylation of 
the PER2 protein (Toh et al., 2001, Xu et al., 2005). Polymorphisms in PER1 and 
PER3 are associated with the diurnal preference and delayed sleep phase syndrome 
(DSPS) (Ebisawa et al., 2001, Archer et al., 2003, Carpen et al., 2005). A mutation in a 
transcriptional factor, BHLHE41 (DEC2) gene has been associated with short sleep, 
both in humans and mice (He et al., 2009). Furthermore, the 3111T/C polymorphism of 
CLOCK was proposed to have a role in sleep disregulations in mood disorders (Serretti 
et al., 2003). MDD patients with the C allele were reported to be more prone to suffer 
from insomnia while BP patients with the same allele showed insomnia throughout the 
whole night and a reduced need for sleep (Serretti et al., 2003).  In addition, in another 
study, this CLOCK polymorphism was associated to the time course of insomnia dur-
ing antidepressant treatments (Serretti et al., 2005). Other circadian genes such as 
NPAS2, CRY2, and PER2 polymorphisms have also been reported to associate with 
MDD (Soria et al., 2010, Lavebratt et al., 2010). In addition, circadian clock-related 
polymorphisms were involved in susceptibility to seasonal affective disorder (SAD) 
and diurnal preference (morningness-eveningness) tendencies (Johansson et al., 2003). 
The individuals with a behavioural preference for “eveningness” have a greater ten-
dency to develop depression (Barnard and Nolan, 2008). 
 
Heritability of sleep. A study on 2238 monozygotic (MZ) and 4545 dizygotic (DZ) 
adult Finnish twins demonstrated that the self-reported sleep duration and sleep 
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quality have heritability estimate, 44% in both (Partinen et al., 1983), whereas the 
heritability for sleep quality in Australian twin pairs was 33% (Heath et al., 1990). 
Moreover, twin studies have demonstrated that human EEG heritability during wak-
ing was 81% (van Beijsterveldt and van Baal, 2002), while heritability of EEG du-
ring NREM sleep was even 96% (De Gennaro et al., 2008).  
 
2.2.2  Epidemiology of sleep 
 
An epidemiological study of self-reported sleep duration suggests that 18-25% of 
the population suffer from insufficient or poor sleep (Kronholm et al., 2006). A 
Finnish twin study suggests that sleeping less than 7 hours per night increases an 
incidence of depressed mood (Paunio et al., 2009). Several epidemiological studies 
suggest that sleeping from 7 to 8 hours per night is considered optimal for health, 
since self-reported sleep durations of less than 7 hours or more than 8 hours are 
linked with increased morbidity and mortality (Hublin et al., 2007, Wallander et al., 
2007, Kronholm et al., 2011). According to a cross-sectional population-based study 
conducted in the United States, 28.3% reported sleep durations of 6 hours or less, 
while 8.5% reported sleep durations of 9 hours or more (Krueger and Friedman, 
2009). The prevalence of short sleepers (≤ 6 hours) in the Finnish adult population 
was estimated to be 14.5% (16.7% of men and 12.5% of women) and that of long 
sleepers (≥ 9 hours) 13.5% (10.5% of men and 16.1% of women) (Kronholm et al., 
2006). Studies based on sleep diary data and self-reported sleep duration have also 
shown that women overall sleep more than men, while their sleep quality is lower 
compared to that of men (Krueger and Friedman, 2009, Chatzitheochari and Arber, 
2009). Insomnia is also more prevalent in women (14.9%) than in men (7.4%) 
(Hublin and Partinen, 2002, Ohayon and Partinen, 2002). The gender differences in 
sleep duration or poor quality of sleep may arise due to factors like sociological, 
physiological, and hormonal characteristics (Dzaja et al., 2005, Arber et al., 2009). 
 
2.2.3 Etiology and pathophysiology 
 
Functional regulation of sleep is essential for a healthy life, and genetic factors are 
likely to contribute to a susceptibility to develop disturbed sleep (see in section 
2.2.1.3). Several neurotransmitter pathways are involved in the regulation of the 
sleep-wake cycle. Monoaminergic neurons are active during wakefulness, will slow 
down during NREM sleep, and remain inactive during REM sleep (Saper et al., 
2005). Destruction of serotonergic neurons of the raphe nuclei leads to severe in-
somnia (Jouvet, 1999). There is also evidence that catecholamines play a role in 
sleep and waking (Irwin et al., 1999). The dopaminergic system plays important role 
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in behavioral wakefulness (Monti and Monti, 2007). An increase in the extracellular 
level of dopamine metabolites (DOPAC and HVA) is seen in the BF during sleep 
deprivation (SD), indicating maximum dopamine release during waking (Zant et al., 
2011). The HPA-axis hyperactivity, with an increase in ACTH and cortisol secretion, 
and CRF response to stress (see in section 2.1.3, HPA-axis) is associated with sleep 
disturbances: sleep fragmentation, night-time awakenings or shortened sleep time, 
and decreased slow-wave sleep (Buckley and Schatzberg, 2005, Hudson and Bush, 
2010). GABAergic cells in the anterior hypothalamus and basal forebrain are most 
active during sleep (Gritti et al., 1994), and lesions along this pathway (containing 
hypothalamic area, basal forebrain, and cerebral cortex) produce sleepiness or coma 
(Saper et al., 2005).  
 
2.3  Sleep and mood  
 
Disturbed sleep is one of the symptoms of depressive disorder. It diminishes daily 
happiness and produces depressed mood. However, sleep deprivation or sleep loss 
have mood elevating effects on patients with depression (Wu and Bunney, 1990, 
Adrien, 2002), in whom lower mood was reduced by one night of sleep deprivation, 
while depressive symptoms reoccurred after one night of recovery sleep (Tsuno et 
al., 2005). Among the different phases of sleep, REM sleep is mainly involved in the 
modulation of daily mood. REM sleep pressure is increased in patients with depres-
sion (Vogel et al., 1980). Selective REM sleep deprivation with the according noc-
turnal awakenings over a period of three weeks has shown to induce an antidepres-
sant effect on the mood of depressed subjects (Vogel et al., 1980), while selective 
deprivation of NREM sleep did not lead to clinical improvement (Vogel et al., 1980). 
Several studies have tried to elucidate the mechanisms of action of sleep deprivation. 
There is a persistent reduction in glucose metabolism in the anterior cingulate cortex 
of patients with depression (Smith et al., 1999). According to a PET study, glucose 
metabolism in the cingulate cortex is elevated among those depressed patients who 
improved after sleep deprivation (responders), but not in the nonresponders 
(Riemann et al., 2001). MDD is associated with a decrease in serotonergic neuro-
transmission and increased cholinergic tone which leads to an enhanced REM sleep 
pressure (Adrien, 2002). Sleep deprivation appears to influence also the activity of 
brain serotonin transmission, and prolonged wakefulness is associated with release 
and increased extracellular concentrations of 5-HT (Zant et al., 2011), and down-
regulation of 5-HT1A autoreceptors (Portas et al., 2000). Genetic studies of serotonin 
transporter (SLC6A4, 5-HTTLPR) suggest that patients with depression, homozy-
gous for the L allele, are better responders to sleep deprivation compared to patients 
with the S allele (Benedetti et al., 1999). Thus, the effects of sleep deprivation in 
depressed patients may induce enhancement of serotoninergic neurotransmission, 
REVIEW OF THE LITERATURE 
 
THL — Research 81/2012 47 A Study of Candidate Genes in Depression and Disturbed Sleep 
 
which alleviates REM sleep pressure and leads to significant mood improvement. 
All of these findings suggest that the regulation of sleep and mood are interlinked. 
 
 
2.4 Studying the human genome  
2.4.1 The Human Genome Project (HGP) and the Human Haplotype Map 
Project (HapMap) 
 
Genes are made of deoxyribonucleic acid (DNA) and are found on chromosomes in 
the nucleus of the cell. The genetic instructions contained in a genome are encoded 
in DNA, which has a long sequence of four chemical bases abbreviated as A (ade-
nine), C (cytosine), G (guanine), and T (thymine), called nucleotides (Watson and 
Crick, 1953). At the beginning of the 21st century, two landmarks in the history of 
biomedical sciences were achieved, the Human Genome Project (HGP) 
(www.ornl.gov/hgmis) and the Human Haplotype Map Project (HapMap) 
(http://hapmap.ncbi.nlm.nih.gov/). The HGP was an international research effort to 
sequence the entire human genome in order of nucleotides along the DNA molecule 
in each chromosome (The International Human Genome Sequencing Consortium, 
2004). The sequencing resulted in the current estimate of the number of genes to be 
25,000 and the number of protein coding genes to be over 18,000. The average gene 
consists of approximately 3000 bases (Venter et al., 2001, Lander et al., 2001). In 
the human genome sequence, 99.9% of the bases are identical in all humans, while 
the remaining 0.1% variation makes every individual unique. Table 8 summarizes 
several forms of variations present in the human genome. These variations range 
from single nucleotides to gross alterations in the DNA sequence. Genetic variations 
may have ability to interfere with gene expression and their protein function (Eichler 
et al., 2007). These variations might contribute to new or heritable diseases or have 
an impact on human phenotype (Eichler et al., 2007). 
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Table 8. Types of polymorphisms in the genome [Adapted from (Tabor et al., 2002, 
Feuk et al., 2006, Sharp et al., 2006, Richard et al., 2008, The 1000 Genomes Project 
Consortium, 2011)]. 
Type of variant Functional effect 
1) SNPs  
A) Coding SNPs  
– Synonymous/ Sense/Silent mutation Create a new codon that still codes for the 
same amino acids, does not change the 
amino acid in the protein, but can alter 
splicing 
– Non-synonymous/ Missense /Point mutation Create a new codon that codes for new 
amino acids, changes an amino acid in 
protein to one with similar properties 
– Nonsense/Stop-introducing SNPs Change an amino acid to stop codon results 
in a premature termination of amino acid 
sequence 
B) Noncoding SNPs  
– Promoter/Regulatory (5′ UTR, 3′ UTR) Does not change the amino acid but can 
affect the location, timing or level of gene 
expression 
– Intergenic  SNP could affect transcription factor bind-
ing sites, enhancer regions, and influence 
gene transcription 
– Intronic No known function, but might affect ex-
pression or mRNA stability 
– Splice site/Intron–exon boundary Might change the splicing pattern or effi-
ciency of introns 
2) Insertions/Deletions/Duplication  
– Frameshift  Insertion or deletion of one base in the 
triplet reading frame, changes the frame of 
the protein-coding region 
– Variable number of tandem repeats 
(VNTRS) 
 
• Microsatellite  Short repeats of one to five base pair units, 
or varying from 10 bases up to 500 bases. 
It might influence the regulation of gene 
expression 
• Minisatellites  Consist of tandem repeats spanning ap-
proximately 100 bp to 20 kb in length, 
valuable tools for genetic analysis 
– Copy number variants (CNVs) A segment of DNA that appear in 1kb or 
larger size in different numbers of copies in 
different people 
– Low copy repeat/Segmental duplication A segment of DNA >1 kb in size with 
>90% sequence identity which occurs in 
two or more copies per haploid genome 
 
Single nucleotide polymorphisms (SNPs) are the most researched variations in the 
human genome. These are DNA variations which replace one of the four nucleotides 
for another. In the human genome, SNPs can be found on average in 1 out of every 
300-1000 nucleotides, and are much more common within genes (The International 
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HapMap Consortium, 2003). SNPs are presented most typically as bi-allelic markers, 
out of which the allele with the lower frequency is called the minor allele and one 
with the higher frequency is referred to the major allele. In the human population, 
there are an estimated 11 million SNPs that have minor allele frequencies of 1% 
(Kruglyak and Nickerson, 2001). Currently there are over 52 million SNPs recorded 
on the NCBI dbSNP database (Build 135, released in 2011), of which 41 million are 
validated (http://www.ncbi.nlm.nih.gov/snp). 
 
The International HapMap project was launched in the year 2002 with the aim of 
cataloging and mapping common patterns of human genetic variation (The Interna-
tional HapMap Consortium, 2003). The results of the HapMap project were pub-
lished in three phases (The International HapMap Consortium, 2005, Frazer et al., 
2007, Altshuler et al., 2010). Samples were genotyped from European, African, and 
Asian populations, resulting in an open-access public database for the scientific 
community (http://hapmap.ncbi.nlm.nih.gov/). The HapMap project discovered a 
block-like structure in human genome (Figure 8) with regions of limited diversity. 
The project catalogued allele frequencies in different global populations, identified 
‘tagging SNPs’ (SNPs that tag with haplotype blocks) and created correlation pat-
terns between nearby variants (a phenomenon known as linkage disequilibrium (LD)) 
over 3.5 million SNPs, and produced a resource for LD-based marker selection for 
genetic studies (The International HapMap Consortium, 2005, Frazer et al., 2007). 
For a deeper understanding of the role of inherited human DNA variations, a 1000 
Genomes Project was initiated in 2008 (http://www.1000genomes.org) with the goal 
of increasing the catalog of genomic variations by using next-generation sequencing 
technologies (Durbin et al., 2010). This project will provide information on rare 
variants in specific genes in large disease-or population-based cohorts, new methods 
for accurate imputation of variants in genome-wide association studies (GWAS), 
and offer a platform for studies using genome-wide sequence data (Durbin et al., 
2010). 
2.4.2  Designs for molecular genetic studies 
 
Identification of the underlying genetic risk factors in classical Mendelian monoge-
netic disorders is a relatively straightforward process. Studies on these disorders 
have also shown how single mutated disease genes can be both necessary and suffi-
cient to cause the observed trait. In contrast, identification of genetic risk factors for 
complex diseases (as for example depression, bipolar disorder, diabetes, or cardio-
vascular disease) is far more challenging, as those disregard the single-gene domi-
nant or single-gene recessive Mendelian law. Furthermore, etiology of complex 
disease is heterogeneous, involving both environmental and genetic risk factors 
which may act together or independently (Cardon and Bell, 2001). The yield of ge-
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netic studies on complex traits has remained controversial, partially due to diagnos-
tic uncertainties, to mode of inheritance, incomplete penetrance, multiple disease 
susceptibility loci, variable age of onset, epistasis, assortative mating, gene envi-
ronment interaction, or proportion of phenocopies, study designs such as candidate 
gene studies, and small sample sizes (Nothen et al., 1993). In designing a genetic 
dissection, some crucial choices related to sampling and phenotyping strategies, as 
well as to analytical methods, arise. These will be discussed in the following section. 
 
Sampling 
The sample size is a key determinant when the power of the study is considered. The 
power of a sample to detect significant association is measured by power calculations, 
and positive findings will ideally need to be replicated in bigger samples (Wacholder 
et al., 2004). Careful sampling design is crucial to avoid sampling bias or error. The 
samples used in research should be representative of the population of interest. Vari-
ous sampling strategies are commonly used in molecular genetic studies. 
 
A cross-sectional study is conducted on the entire population or a subset thereof. In 
this type of design, data are collected at a defined time. This kind of sampling can 
provide estimates for disease prevalences. This type of sampling is not suitable for 
rare diseases due to the small number of affected individuals (Cordell and Clayton, 
2005). 
 
A longitudinal cohort design is often used for genetic association studies and is 
useful if the examined trait is relatively frequent in the population, or if it is quanti-
tative by its nature. This study design follows the disease incidence over a long time 
and the participants are observed in order to identify new incident cases of the dis-
ease. This sampling can provide estimates for disease incidence, and collection of 
information from the environment can be achieved easily. However, the follow-up 
of participants is usually expensive and time consuming, and dropout of participants 
occurs during the follow-up. Longitudinal studies are also not ideal for rare diseases 
which require large numbers of study participants (Cardon and Bell, 2001). 
 
A case-control sample strategy has been widely applied in etiological studies on 
complex diseases (Spinka et al., 2005). In this strategy, cases and controls are ascer-
tained from the same population. Case-control sampling is effective in the study of 
rare diseases. Issues such as family history, age of onset, or severity of disease are 
important to consider while selecting cases (Teng and Risch, 1999). In case-control 
samples, differences in the frequency of susceptibility alleles between cases and 
controls can be defined (Hattersley and McCarthy, 2005). The selection of the con-
trol sample is crucial, and issues such as health status, age, and gender must be taken 
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into account. The controls must be selected from the same population as the cases in 
order to avoid findings due to population stratification (Cordell and Clayton, 2005).  
 
A family-based sampling strategy, a sample of parents and their affected and unaf-
fected offspring, is a powerful method to identify genetic associations. In family-
based association approaches, alleles transmitted to affected offspring are compared 
to the nontransmitted alleles (Lange et al., 2008). These types of samples are effi-
cient for the identification of rare, population-specific risk factors, and for the vali-
dation of previously identified genetic factors. The sample design is ideal for avoid-
ing spurious results due to population stratification. Sample collection is, however, 
expensive.  
 
Twin samples can be used to assess genetic and environmental factors, which pro-
duce differences in a trait of interest. If monozygotic twins exhibit higher concor-
dance for a trait as compared to dizygotic, genetic factors are likely to play a role in 
the development of the trait (Kaprio and Koskenvuo, 2002). Twin studies provide 
estimates of trait heritability on the basis of the concordance rates in monozygotic 
and dizygotic twins. The disadvantage of twin sampling is that information about 
zygosity is often not available in medical records, and the sample size is small due to 
the difficulty of getting suitable sets of twins. 
 
Phenotyping 
Phenotypes are the observable characteristics of an organism to which both genetic 
and environmental factors contribute (Rice et al., 2001). Phenotypes can be ob-
served through signs, symptoms, visible traits, and they are often inherently dynamic 
and unstable (Schulze and McMahon, 2004). In genetic research, phenotypic traits 
are basically of two kinds, quantitative and qualitative. Certain traits such as blood 
pressure, weight, or performance scores in a neuropsychological test vary continu-
ously across individuals and can be handled as quantitative traits. Qualitative pheno-
types are usually dichotomized traits that can be described as binary data if there are 
only two categories (as for example cases and controls for a disease). A complex 
disease is genetically heterogeneous that complicates the detection of the disease 
contributing factors (Schork, 1997). Therefore, a common method for identifying 
phenotype is to rely on medically recognized criteria. For example, the diagnosis of 
MDD which depends on DSM criteria show clusters of symptoms and characteris-
tics of clinical course that reliably differentiate depressed patients from normal indi-
viduals (Hasler et al., 2004). Thus, diagnostic assessment of phenotypes requires a 
standard framework of clinical checklists or examination items, questionnaires, and 
laboratory data (Schulze and McMahon, 2004). Several studies have used this 
scheme for the identification of depressive phenotype. Caspi et al (2003) showed 
that 5-HTT genotypes moderate the influence of stressful life events on MDD (Caspi 
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et al., 2003). Thus increased stress sensitivity can be considered to present psycho-
pathological endophenotype for MDD. Sleep disturbances, including insomnia, have 
been found to prominently contribute toward the risk  of developing MDD (Breslau 
et al., 1996). Furthermore, REM sleep abnormalities have been found in patients 
with MDD and they are proposed as biological endophenotypes for genetic studies 
(Hasler et al., 2004). The term endophenotype is understood as any hereditary char-
acteristic that is normally associated with disease but is not a direct symptom of that 
disease (Gottesman and Gould, 2003).  
 
Analytical methods 
Linkage analysis. This analytical method is typically carried out to determine chro-
mosomal locations for disease susceptibility loci by genotyping genetic markers in 
pedigrees with multiple affected individuals. The method helps to reveal the chro-
mosomal region that is transmitted with the disease. In linkage, loci located close 
together on same chromosome are not usually separated by a crossover event (re-
combination) but inherited together during meiosis. The genetic distance between 
two loci is measured by the recombination fraction [θ]. If two loci lie close together, 
θ is 0, while θ is 0.5 if these loci are independently segregating. The logarithm of 
odds (LOD) score is a likelihood ratio test used for calculating the likelihood that 
two loci co-segregate together because of linkage instead of chance (Morton, 1955). 
In genome-wide analyses, evidence of linkage to depression has been found for 
several genomic regions including 1p36, 12q23.3-q24.11, 13q31.1-q31.3 (McGuffin 
et al., 2005), 15q25.3-26.2 (Holmans et al., 2004), 3p12.3-q12.3, 18q21.33-q22.2 
(Camp et al., 2005), and 3p26-3p25 (Breen et al., 2011). 
 
Association analysis. In this method, the frequencies of alleles, genotypes or haplo-
types of genetic markers are compared between groups of people with a certain dis-
ease to a control group of people without the disease. This method allows the detec-
tion of genetic effects in samples of various types, including case-control samples to 
population-based cohorts or family-based samples. A minor bias in sample ascer-
tainment can produce errors in the estimates of allele frequencies. In addition, test-
ing of multiple genetic markers tends to increase the risk for false positive results. 
Therefore, replication of results is usually required to confirm an association. To 
avoid population stratification effects, cases and controls have to be carefully 
matched regarding their geographical, social, and ethnic background (Nothen et al., 
1993). As compared to linkage analysis, association analysis has a greater statistical 
power to discover variants with relatively small effect (Risch and Merikangas, 1996). 
The effect size in association analyses is measured by the odds ratio (OR), defined 
as ‘the odds of exposure among cases divided by the odds of exposure among con-
trols’ (Zondervan and Cardon, 2004). The value OR=1 means that exposed indi-
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viduals are at no increased risk compared with the controls. OR>1 indicates an in-
creased risk and OR<1 implies protective effect (Zondervan and Cardon, 2004).  
 
An association study using a candidate gene approach is based on a prior hypothesis 
that a candidate gene has an etiological role in a disease. The selection of variants is 
based on the structure of the gene, in which linkage disequilibrium (LD) between 
markers in the region of a gene is taken into account. If variants are in complete LD, 
it is possible to deduct their genotypes on the basis of a single genotype (Figure 8). 
This strategy covers a relatively wide range of genetic variation in the region at a 
reasonable cost. LD can be observed in a population as block like structures, such as 
haplotype or LD blocks (The International HapMap Consortium, 2005). LD is a 
measure of two alleles segregating together (positive LD) or not. The most com-
monly used measures for LD, pair-wise method, which is denoted as the D prime 
measure of LD (D’), or as the squared correlation coefficient (r2). The value of both 
D’ and r2 of 0 suggests that two markers have been separated by recombination. 
Furthermore, both D’ and r2 equal 1 suggests that the markers are in complete LD. 
Recombination events may break down LD in successive generations (Hill and Rob-
ertson, 1966). Therefore, a random marker within, or in close proximity to, a gene 
may not necessarily be in a complete LD with a disease-predisposing mutation in the 
same gene. In particular, reconstructing single nucleotide polymorphism haplotypes 
and testing those for an association to the disease should help in refining the chro-
mosomal background on which the actual disease-predisposing mutation occurs 
(Daly et al., 2001).  
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Figure 8. Haplotypes and linkage disequilibrium (LD) in SNP selection [Figure 
modified from (Tabor et al., 2002)]. The figure represents a set of consecutive SNPs 1-
4 cluster together on a chromosome which is inherited as a block so called haplotype. 
SNPs 1-4 are in LD and form two common haplotypes “CAAA” and “TGTG” which can 
be identified by the genotype of one of the SNPs and tested for association indirectly as 
it is in LD with the other three SNPs.  
A genome-wide association study (GWAS) is based on a large amount of genotyp-
ing, including hundred of thousands, or even up to a million SNPs distributed 
throughout the genome. The GWAS era arrived with the proposed hypothesis of the 
“common-disease common-variant” (Lander, 1996). This theory suggests that the 
susceptibility genes in common complex diseases represent common SNPs of small 
effects but with high frequency in the general population. Information on LD is used 
to select a non-redundant set of SNPs for genotyping so that approximately 80% 
SNPs of the genome variation is tagged by the GWAS platforms (Kruglyak, 2008). 
Thus far, GWA studies conducted on MDD, (Sullivan et al., 2009, Lewis et al., 
2010, Muglia et al., 2010, Wray et al., 2010, Shi et al., 2011, Shyn et al., 2011), 
have failed to achieve genome-wide significance. This is ascribed to inadequate 
sample sizes, genetic heterogeneity, and inadequate effect size of the risk variants, 
which together results in insufficient statistical power.  
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3 AIMS OF THE STUDY 
Depression comprises a variety of symptoms, including early morning awakenings 
and fatigue, which are also signs of disturbed sleep. Several neurobiological mecha-
nisms have been indicated in regulation of sleep and induction of depression. Pres-
ence or absence of disturbed sleep symptoms may reflect differences in the neurobi-
ological processes that lead to depression. The main aim of this study was to identify 
genetic variants predisposing to depression and disturbed sleep in the Finnish popu-
lation by using a candidate gene strategy.  
 
 
The specific aims of this thesis were:  
 
I. To examine the association of polymorphisms in genes that are functionally re-
lated to serotonergic and glutamatergic neurotransmission systems, to neural plastic-
ity and to the HPA-axis, in depression and disturbed sleep. 
 
II. To examine the association of polymorphisms in genes involved in the circadian 
system in depression and disturbed sleep, and in seasonal variations in mood and 
behavior. 
 
III. To elucidate the role of genetic variants associated with depression and disturbed 
sleep (from studies I and II) in the regulation of sleep in healthy individuals. 
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4 SUBJECTS AND METHODS 
4.1 Study subjects 
 
The subjects of this thesis study were recruited from a cross-sectional, nation-wide 
population-based health interview and examination survey Health 2000 (studies I-
III) and FINRISK study 2007 survey (study III). Detailed information about these 
two cohorts can be found at (http://www.terveys2000.fi/indexe.html) and 
(http://www.ktl.fi/portal/4168). The Institutional Review Board of the Helsinki and 
Uusimaa Hospital District approved the study. All participants provided full in-
formed consent for the collection of blood samples and subsequent analyses. 
 
Subjects from Health 2000 program  
The Health 2000 program is a nationwide population-based health survey carried out 
in Finland between the fall of 2000 and spring of 2001 by the National Institute for 
Health and Welfare (THL). Nationally representative samples of 10,000 individuals 
have been drawn from the population aged 18 and over. The aim of the Health 2000 
program was to create a solid informational basis on the state of health and disease 
in Finland (Aromaa and Koskinen, 2004). The health status of all study subjects was 
evaluated by an interview conducted at home and a health examination at the local 
healthcare centre. The participants were asked to fill in questionnaires at home and 
to bring them along to the local healthcare center for a health examination. The 
health interview included questions on previous illnesses, healthcare use, medica-
tions, living environment, and socioeconomic factors. The trained nurses and physi-
cians of five university hospital divisions (1: Helsinki and Uusimaa, 2: Varsinais-
Suomi, 3: Pirkanmaa, 4: Pohjois-Savo, 5: Pohjois-Pohjanmaa) monitored the health 
status of all subjects. The health examination comprised standardized symptom in-
terviews, laboratory sampling, blood pressure measurement, and mental health in-
terviews. The stages of the health examination are summarized in table 9. To maxi-
mize the participation rate in the survey, advertisements in the media, telephone 
calls, interviews at home, and mailed reminders were used. Of the study population 
aged 30 and over, 89% participated in the interviews at home and 85% in the health 
examination. Of the study population’s young adults aged 18 to 29 years, 80% were 
interviewed, which included the symptom interview (Aromaa and Koskinen, 2004). 
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Table 9. Flow chart of the health examination in the Health 2000 survey [Adapted 
from (Aromaa and Koskinen, 2004)]. 
Time Activities  By Field Personnel 
AT HOME  
90 minutes  INTERVIEW (by Statistics Finland’s interview or-
ganization) 
30 minutes FILLING IN QUESTIONNAIRE 1  
[Questionnaire 1 retrieved information on: functional 
capacity and quality of life, use of time and leisure 
activities, physical activity, alcohol consumption, 
mental health as well as perceived strain at work and 
burnout] 
AT HEALTHCARE 
CENTRE 
( 3hours and 15 minutes) 
 
15 minutes 1 RECEPTION  
- information, informed consent, symptom interview 
[covered respiratory and cardiovascular symptoms, 
allergies and musculoskeletal symptoms] 
- handing Questionnaire 2 and the urine sample con-
tainer 
15 minutes 2 MEASUREMENTS: height, body circumference, 
ECG, blood pressure  
15 minutes 3 MEASUREMENTS: spirometry, bioimpedance, 
heel bone density  
15 minutes 4 LABORATORY  
- drawing blood samples (100 ml), handling of sam-
ples 
15 minutes 5 ORAL EXAMINATION 
- clinical oral examination, orthopantomography 
15 minutes SNACK, FILLING IN QUESTIONAIRE 2  
[Questionnaire 2 retrieved information on: gastroin-
testinal diseases, respiratory diseases and vaccina-
tions] 
30 minutes 6 FUNCTIONAL CAPACITY TESTS 
- physical and cognitive capacity, vision and hearing 
30 minutes 7 CLINICAL  EXAMINATION 
30 minutes 8 MENTAL HEALTH INTERVIEW  
15 minutes 9 FINAL INTERVIEW  
- checking that all examinations and questionnaires 
have been completed 
- handing Questionnaire 3 and Dietary Questionnaire 
- information about the previous and possible further 
examinations 
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AT HOME (100 minutes) (HEALTH EXAMINATION FOR THOSE NOT 
ATTENDING THE HEALTH EXAMINATION 
PROPER AT THE HEALTHCARE CENTRE ETC.)  
40 minutes FILLING IN QUESTIONNAIRE 3  
[Questionnaire 3 retrieved information on: sleep and 
sleeping, seasonal variation, mental health problems, 
emotions and feelings, health-related quality of life, 
driving, alcohol, attitudes regarding health etc.]  
FILLING IN DIETARY QUESTIONNAIRE 
[Dietary questionnaire  retrieved information on: 
milk products, cereal products, vegetables, meat and 
fish dishes fruits and beverages] 
AT UNIVERSITY HOS-
PITALS AND RE-
SEARCH INSTITUTES 
FURTHER EXAMINATIONS FOR SUBSAMPLES 
FROM REGISTERS REGISTER DATA 
The details of sampling design, target population, and methods of the survey have been 
reported elsewhere (http://www.ktl.fi/terveys2000/index.uk.html). 
 
Health 2000. In studies I and II, 1654 subjects (967 females and 687 males) with a 
minimum age of 30 years were included from the Health 2000 survey. Of these sub-
jects, 384 belonged to the depression group (D+) (259 females, mean age 49 years, 
and 125 males, mean age 48 years). Among these cases, 109/259 females and 
61/125 males also reported early morning awakenings (group D+EMA+). The corre-
sponding numbers for fatigue were 194 and 103 (group D+FAT+), whilst 94 females 
and 58 males belonged to both groups, D+EMA+ and D+FAT+. 
 
In the control group (D–), there were 1270 individuals (708 females, mean age 46 
years, and 562 males, mean age 45 years) with no depression or any other psychiat-
ric disorders. The controls were matched by their age and gender to the cases 
(n=384) and comprised 392 additional individuals from the general population who 
did not have any sleep related problems or mental disorders. Altogether the control 
groups included 705 females and 561 males with no signs of early morning awaken-
ings (group D-EMA-), and 580 females and 482 males with no signs of fatigue 
(group D-FAT-). Moreover in study II, information on the global seasonality scores 
(GSS) was available for 967 females and 687 males from the total sample of 1654 
subjects. 
 
Genmets (D-) sample. In study II, a secondary or independent sample set drawn 
from the Health 2000 program was included, which was originally selected for a 
study on metabolic disorders. Of these samples, 141 cases had a CIDI-based diagno-
sis of depression. They were excluded and referred to as the Genmets (D-) sample. 
Within the secondary sample, the genetic information was available for 1512 indi-
viduals (759 females, mean age 53 years, and 753 males, mean age 47 years). There 
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were 314 females and 311 males with a metabolic syndrome, which was controlled 
for as a covariate status in the analyses. Furthermore, 695/759 females and 691/753 
males had provided information on the GSS. The corresponding numbers for other 
studied phenotypes in the Genmets (D-) sample are presented in table 10. 
 
Subjects from FINRISK study 2007 survey 
 
This survey was carried out in 2007 in Finland for the study of chronic diseases, 
coronary risk factors, and health behaviour (http://www.ktl.fi/portal/4168). The first 
phase of the study took place from January to March and involved a total of 6258 
subjects (a response rate of 63%) (Konttinen et al., 2010). The second phase of this 
study survey was conducted from April to June 2007, the goal of which was to in-
vestigate the Dietary, Lifestyle and Genetic Determinants of Obesity and Metabolic 
Syndrome (DILGOM sub study).  Of the 5024 individuals who took part in this 
phase of the study, the response was 84% (Konttinen et al., 2010). This study in-
cluded 655 healthy individuals from the Helsinki-Vantaa region, originally matched 
as controls for a cardiovascular risk factor study. 
  
Combined sample set (Health 2000 program and FINRISK study 2007 survey). 
Altogether 3147 healthy individuals (1626 females, mean age 51 years, and 1521 
males, mean age 49 years) were included in study III, which were pooled from the 
following three subsamples with information on sleep duration (Table 10): 
 
• 1135 individuals (610 females and 525 males) from the studies I and II 
with no depression and no complaint of disturbed sleep (Health 2000, Con-
trol group). 
 
• 1357 individuals (690 females and 667 males) from the Genmets (D-) 
sample, from study II. 
 
• 655 healthy individuals (326 females and 329 males) from the national 
FINRISK study 2007 survey.  
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Table 10. Characteristics of study subjects.  
 set Study phenotypes Study subjects 
2000 Dichotomized variables     
Cases Females Age 
(Average ± SD) 
Males Age
(Av
Depression (D+) (All) 259 49.02±13.65 125 47.
Early morning awakenings (D+EMA+) 109a 51.64±13.19 61b 48.
Fatigue (D+FAT+) 194a 50.10±14.06 103b 48.
Controls     
No depression (D-) (All) 708 46.35±11.80 562 44.
Controls without early morning awakenings (D-EMA-) 705 46.32±11.80 561 44.
Controls without fatigue (D-FAT-) 580 46.10±11.68 482 45.
ts 
mple 
Additional Controls     
Controls with early morning awakenings (D-EMA+) 274c 56.87±10.38 248d 54.
Controls with fatigue (D-FAT+) 388c 56.24±10.22 342d 48.
Controls without early morning awakenings (D-EMA-) 412 69.05±7.77 419 48.
Controls without fatigue (D-FAT-) 349 56.97±10.48 383 53.
ned  
 set 
Quantitative traits     
Sleep duration (All) 1626 51 ± 13 1521 49 
Short sleepers 195 54 ± 15 234 49 
Midrange sleepers 1220 50 ± 13 1156 48 
Long sleepers 211 47 ± 16 131 55 
Overlap in the Health 2000 samples with D+EMA+ and D+FAT+ was a94 for females and b 58 for 
males. Overlap in the Genmets (D-) sample with D-EMA+ and D-FAT+ was c165 for females and 
d136 for males.  
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4.2 Phenotyping methodology 
 
Only individuals that answered the diagnostic questions regarding the MDD, dis-
turbed sleep, and the sleep duration, were included in this study. 
 
The composite international diagnostic interview (I-II) 
 
In studies I and II, a Finnish translation of the German, computerized version of the 
Composite International Diagnostic Interview (M-CIDI) was used  (Pirkola et al., 
2005). This program uses operationalized criteria for Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition (DSM-IV) diagnoses and allows estimation 
of DSM-IV diagnoses for major mental disorders (Pirkola et al., 2005). In this study, 
a 12-month prevalence of major depressive episodes was used as a diagnostic, in 
addition to dysthymic disorder (see in section 2.1.2.1). The interviewers were non-
psychiatric health care professionals who had been trained for 3-4 days by psychia-
trists and physicians who had been authorized by the World Health Organization 
(WHO) (Ahola et al., 2005). The individuals with no complaints of disturbed sleep, 
and no depression or any other psychiatric disorder according to the CIDI using the 
DSM-IV criteria (American Psychiatric Association, 1994), were referred to as 
healthy individuals or controls (group D–) in studies I-III. 
 
Assessment of early morning awakenings and fatigue (I-II) 
 
Symptoms of early morning awakenings (EMA) and fatigue, which would point to 
disturbed sleep in depression, were questioned systematically in the interview (Table 
11). Those who agreed to the scored question “Do you wake up in the middle of 
sleep very early in the morning?” (KYS3_K03), and felt that this happened either 
“often” or “almost every night” were coded as positive for the EMA feature. For the 
assessment of fatigue, three different items from the questionnaire were clustered 
into a single item in order to have a more robust estimation of fatigue. Those who 
felt either (i) “nearly always” or “often more tired than generally people of the same 
age” (KYS3_K04) or (ii) “powerless”, “fatigued” (KYS1_K1305) or “overstrained”, 
“burned-out” (KYS1_K1307) to some extent, quite a lot, or very much during the 
last 30 days, were coded as positive for the feature of fatigue. 
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Table 11. Questionnaire for assessment of EMA and fatigue.  
Phenotype Question Explanation Coding 
YES 
Coding 
NO 
Early morn-
ing awaken-
ings (EMA) 
KYS3_K03: 
Do you wake 
up in the mid-
dle of sleep 
very early in 
the morning? 
1= Not at all 
2 = Now and 
then 
3 = Often 
4 = Almost 
every night 
3,4 1,2 
Fatigue *KYS3_K04: 
Do you con-
sider yourself 
to be fatigued 
more often 
than other 
people of the 
same age 
during the 
daytime? 
 
 
*KYS1_K130
5: Powerless 
or fatigued 
 
*KYS1_K130
7: Over-
strained or 
burned-out 
1 = Yes, 
nearly  
always 
2 = Yes, 
very often  
(at least 
weekly) 
3 = No 
4 = I can not 
say 
 
 
1 = Not at all 
2 = A little 
3 = To some 
extent 
4 = Quite a 
lot 
5 = Very 
much 
 
KYS3_K04 
 = 1,2 
KYS1_K1305  
= 3,4,5 
KYS1_K1307 
 = 3,4,5 
KYS3_K04  
= 3,4 
KYS1_K1305 
= 1,2 
KYS1_K1307 
= 1,2 
*1 missing value allowed; if ≥2 missing values and the criteria for “YES” are not fulfil-
led, item encoded as “UNKNOWN”. 
 
Assessment of global seasonality score (GSS) (II) 
 
Study participants also completed the Seasonal Pattern Assessment Questionnaire 
(SPAQ) (Rosenthal NE et al., 1984); a self-report instrument for the assessment of 
seasonal changes in the length of sleep, social activity, mood, weight, appetite, and 
energy level whose sum yields the global seasonality score (GSS) (Lahti et al., 
2008). These items were scored ranging from 0 to 24; over 10 or more points indi-
cate greater seasonality changes. A seasonal variation in mood and behaviour was 
measured with a two-factor solution for the global seasonality score (GSS). Factor 1 
was considered as a metabolic factor (GSSf1) including items on weight and appe-
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tite, and factor 2 as a mental factor (GSSf2) including items concerning sleep dura-
tion, social activity, mood, and energy level (Rintamaki et al., 2008). 
 
Sleep duration (III) 
 
Sleep duration in healthy subjects was assessed using the self-reported question 
(KYS3_K01) “How many hours do you sleep on average during 24 hours?” The 
participants were classified according to their duration of sleep as ‘short sleepers (6 
hours or less)’, ‘midrange sleepers (7-8 hours)’, and ‘long sleepers (9 hours or 
more)’.  
 
4.3 Candidate genes and marker selection 
 
Study I focused on the candidate genes from the serotonergic (TPH2, SLC6A4, COMT 
and MAOA), glutamatergic (GAD1, P2RX7, DAOA and GRIA3), neural plasticity 
(DISC1, CREB1, NTRK2 and BENF), and HPA-axis systems (NR3C1 and CRHR1). 
The polymorphisms of the candidate genes investigated are listed in table 12.  
 
Table 12. List of the studied candidate genes and the SNPs in study I. 
Gene  
Symbol  
Chr SNP Position Role A.A Alleles 
Serotonergic system      
TPH2 12q21.1 rs11178997 70618420 Promoter - T/A 
  rs10748185 70622122 Intron - A/G 
  rs1386492 70648532 Intron - T/C 
  rs7305115 70659129 Exon PRO/ 
PRO 
G/A 
  rs12229394 70679181 Intron - G/A 
  rs4760820 70683263 Intron - C/G 
  rs10879354 70696049 Intron - T/C 
  rs1487275 70696559 Intron - A/C 
  rs4290270 70702502 Exon ALA/
ALA 
T/A 
SLC6A4 17q11.2 rs3794808 25555919 Intron - C/T 
  rs140700 25567515 Intron - C/T 
  Intron 2 VNTR 
(STin2VNTR) 
25572535 Intron - 9R/10R/
12R 
  rs6354 25574024 Exon - T/G 
  rs4251417 25575984 Intron - C/T 
  5-HTTLPR 25588443 Promoter  -  L/S 
  rs25531 28564350 Promoter - A/G 
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COMT 22q11.21 rs4680 18325825 Exon  VAL/
MET 
A/G 
  rs165599 18331335 3' UTR  - A/G 
MAOA Xp11.3 MAO-A-30 bp 
VNTR 
43270603 Promoter - 3R/3.5R
/4R 
/5R 
  rs1465108 43294463 Intron - G/A 
  rs5906957 43303564 Intron - G/A 
  rs6323 43347290 Exon ARG/
ARG 
T/G 
Glutamatergic system      
GAD1 2q31 rs12185692 171496333 Promoter - C/A 
  rs2241165 171503886 Intron - T/C 
  rs2058725 171515628 Intron - T/C 
  rs769407 171519215 Intron - G/C 
  rs3791850 171533607 Intron - G/A 
P2RX7 12q24 rs591874 120034185 Intron - A/C 
  rs1718125 120055739 Intron - C/T 
  rs208290 120056776 Intron - G/A 
  rs208294 120062973 Intron - C/T 
  rs504677 120067909 Intron - C/T 
  rs1718119 120077823 Exon - G/A 
  rs2230912 120084916 Exon - A/G 
DAOA  13q34 rs2391191  104917447 Exon ARG/
LYS 
G/A 
  rs12874006 104918986 Intron - G/T 
  rs1539070 104922458 Intron - C/G 
  rs2153674 104929139 Intron - C/T 
  rs701567 104939996 Intron - T/C 
  rs12864685 104941856 3' UTR  - C/T 
  rs778326 104948042 3' UTR - A/T 
  rs954580 104949855 3' UTR - T/C 
  rs778330 104952561 Intron - A/G 
  rs778336 104954515 Intron - C/T 
  rs778293 104967200 Intron - T/C 
GRIA3 Xq25 rs6649004 122204322 Intron - T/C 
  rs5911611 122237152 Intron - G/A 
  rs526716 122272504 Intron - C/T 
  rs3848874 122298920 Intron - G/A 
  rs687577 122304639 Intron - C/A 
Neural Plasticity system     
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DISC1 1q42.1  rs751229 228075274 Intron - T/C 
  rs3738401 228137030 Exon ARG/
GLN 
G/A 
  rs821616 228451333 Exon SER/ 
CYS 
A/T 
  rs1411771 228481510 Exon - T/C 
CREB1 2q34  rs2709356 208237598 Intron - C/T 
  rs10932201 208251763 Intron - G/A 
  rs11904814 208252304 Intron - T/G 
NTRK2  9q22.1  rs1025743 84544671 Intron - C/T 
  rs1187362 84567821 Intron - A/T 
  rs4144551 84599165 Intron - A/G 
  rs3654 84660045 Intron - T/C 
  rs7038236 84717956 Intron - C/A 
  rs11140793 84721034 Intron - A/C 
  rs1221 84722164 Intron - C/T 
  rs3739570 84867132 3' UTR  - G/A 
BDNF 11p13  rs2203877 27627486 3' UTR  - C/T 
  rs6265 27636492 Exon VAL/
MET 
C/T 
  rs11030102 27638172 Intron - C/G 
  rs11030108 27652040 Intron - G/A 
  rs6484320 27659764 Intron - A/T 
  rs1491850 27706301 Promoter  - T/C 
  rs1491851 27709339 Promoter - C/T 
HPA-axis system      
NR3C1  5q31.3  rs9324916 142702853 Intron - C/G 
  bclI 142758768 Intron - G/C 
  rs10052957 142766894 Promoter  - C/T 
CRHR1  17q21.31 rs173365 41256855 Intron - G/A 
  rs16940665 41263677 Exon THR/
THR 
T/C 
  rs1876828 41267306 Intron - C/T 
Chr-Chromosome, SNP-Single nucleotide polymorphism, A.A-Amino acids. SNPs in-
formation from the NCBI dbSNP BUILD 125.  
 
Study II focused on candidate genes from the circadian system. Altogether 18 can-
didate genes were included. The polymorphisms of the candidate genes investigated 
are listed in table 13.  
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Table 13. List of the studied candidate genes and the SNPs in study II. 
Gene  
Symbol  
Chr SNP Position Role A.A Alleles 
PER3  1p36.23 rs3753503 7764558 Promoter  - G/A 
  rs228729 7768282 Intron  - C/T 
  rs228682 7778933 Intron  - T/C 
  rs228642 7785880 Intron  - T/C 
  rs1891217 7794436 Intron  - C/T 
  rs17374292 7803821 Intron  - C/T 
  rs12035969 7815433 Intron  - C/T 
  rs10462021 7819720 Exon HIS/ 
ARG 
A/G 
PER2  2q37.3 rs881933 238815780 Downstream   - C/G 
  rs934945 238819792 Exon GLY/
GLU 
C/T 
  rs6431590 238829867 Intron  - T/C 
  rs3739064 238841125 Intron  - A/G 
  rs11894535 238841812 Intron  - G/A 
  rs10462023 238849320 Intron  - C/T 
  rs2304672 238851328 5’ UTR  - C/G 
  rs4663302 238868500 Promoter  - C/T 
NPAS2  2q11.2  rs6722909 100827527 Intron  - A/G 
  rs1811399 100845446 Intron  - A/C 
  rs12712083 100875331 Intron  - A/G 
  rs2117714 100888209 Intron  - A/G 
  rs6725296 100904136 Intron  - G/A 
  rs3820785 100914246 Intron  - A/G 
  rs12712085 100931583 Intron  - A/G 
  rs17025078 100946008 Intron  - G/A 
  rs2305160 100957736 Exon THR/
ALA 
G/A 
  S471L 100960623 Exon SER/ 
LEU 
C/T 
  rs1374324 100980754 3' end  - G/A 
CLOCK  4q12  rs10462028 55993057 Downstream   - G/A 
  rs1801260 55996126 3' UTR  - A/G 
  rs11932595 56018354 Intron  - T/C 
  rs6850524 56076754 Intron  - C/G 
  rs4864548 56108560 Promoter  - G/A 
NFIL3  9q22.31  rs1619450 93208976 3' UTR  - T/C 
  rs10991925 93217461 Intron  - A/G 
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  rs2440589 93218808 Intron  - G/A 
  rs968821 93227455 Promoter  - C/G 
  rs813498 93228207 Promoter  - T/C 
BHLHE40  3p26  rs908078 4999771 Exon GLY/
GLY 
T/C 
  rs11130215 5001008 Exon  - A/G 
  rs2137947 5005961 3' UTR  - T/C 
CRY2  11p11.2 rs10838524 45826753 Intron  - A/G 
    rs7123390 45847994 Intron  - G/A 
    rs10838527 45859770 3' UTR   - A/G 
    rs3824872 45862181 Downstream   - C/A 
ARNTL  11p15.2  rs2279287 13255061 Promoter  - C/T 
    rs7950226 13274715 Intron  - A/G 
    rs10766074 13275142 Intron  - T/C 
    rs1982350 13306707 Intron  - G/A 
    rs6486121 13312346 Intron  - C/T 
    rs1562438 13320776 Intron  - C/T 
    rs2290036 13336364 Intron  - T/C 
    rs1868049 13340258 Intron  - C/T 
    rs11022778 13347436 Intron  - T/G 
    rs3816358 13348048 Intron  - C/A 
    rs4757151 13348789 Intron  - G/A 
    rs2278749 13354454 Intron  - T/C 
    rs3897902 13358379 Intron  - A/C 
    rs969485 13359619 Intron  - A/G 
ARNTL2 12p11.23 rs10842905 27374170 Promoter  - T/C 
    rs7137588 27375106 Promoter  - C/G 
    rs4964052 27380597 Intron  - G/T 
  rs922270 27396218 Intron  - T/C 
  rs17413842 27414190 Intron  - A/G 
  rs4964060 27424634 Intron  - G/A 
  rs7304939 27435612 Intron  - C/T 
  rs12299407 27440450 Intron  - T/C 
  rs1037921 27444833 Exon ASN/
SER 
A/G 
  rs4931075 27456413 Intron  - G/A 
  rs2289709 27464900 Downstream   - C/T 
BHLHE41  12p12.1 rs1048155 26164355 3' UTR   - C/G 
TIMELESS  12q13.2  rs2291739 55100920 Exon PRO/
LEU 
T/C 
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    rs2291738 55101548 Intron   - G/A 
    rs7486220 55123683 Intron    - G/A 
    rs1082214 55132757 Promoter  - C/T 
CRY1  12q23.3  rs2287162 105905035 Downstream   - C/G 
    rs2287161 105905270 Downstream   - G/C 
    rs10861683 105905690 Downstream   - T/A 
    rs11113179 105976915 Intron  - G/A 
    rs3809237 106011042 5' UTR  - A/G 
RORA  15q22.2  rs2290430 58579246 Intron  - A/C 
    rs12914584 58605378 Intron  - A/C 
    rs2028122 58628567 Intron  - G/A 
    rs4775281 58631063 Intron  - T/G 
    rs4774370 58680723 Promoter  - T/C 
    rs1863270 58799551 Intron  - T/G 
    rs11637301 58835190 Intron  - T/A 
    rs341373 58900506 Intron  - G/A 
    rs8027829 58961163 Intron  - C/T 
    rs16943429 59066545 Intron  - A/G 
    rs1568717 59149739 Intron  - G/T 
    rs893287 59181524 Intron  - C/T 
    rs4774388 59254290 Intron  - A/G 
    rs1816624 59256614 Intron  - A/G 
    rs6494251 59301859 Intron  - C/T 
    rs10438343 59310872 Promoter  - G/A 
TIPIN  15q22.31 rs3759785 64412524 3' UTR  - G/A 
    rs3759786 64416457 Exon ALA/
SER 
G/T 
  rs2063690 64428786 Exon ALA/
GLY 
C/G 
  rs8031897 64433145 Intron  - T/C 
NR1D1  17q11.2 rs2314339 35506738 Intron  - G/A 
    rs2071427 35508018 Intron  - G/A 
    rs2269457 35508215 Intron  - T/C 
    rs2071570 35510616 Promoter  - C/A 
PER1  17p13.1  rs2289591 7988735 Intron   - G/T 
    rs2253820 7988894 Exon THR/
THR 
G/A 
    rs3027188 7989710 Intron  - G/C 
    rs885747 7991462 Intron  - G/C 
    rs2518023 7997331 Promoter  - G/T 
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DBP  19q13.33 rs3745733 53824446 Exon  - G/A 
CSNK1E  22q13.1 rs135745 37013583 3' UTR  - G/C 
    rs2075984 37020835 Intron  - A/C 
    rs5750581 37025352 Intron  - T/C 
    rs7289981 37049908 Promoter  - C/T 
Chr-Chromosome, SNP-Single nucleotide polymorphism, A.A-Amino acids. SNPs in-
formation from the NCBI dbSNP BUILD 125 and 129. 
 
In study III, we examined 23 SNPs from 12 candidate genes; TPH2 (rs12229394), 
SLC6A4 (rs4251417), GRIA3 (rs687577, rs526716), DISC1 (rs3738401), BDNF 
(rs6265, rs1491850), CRHR1 (rs173365), NPAS2 (rs12712083), NFIL3 (rs1619450), 
ARNTL (rs6486121, rs3816358, rs969485), ARNTL2 (rs4964060, rs7304939, 
rs1037921, rs2289709), TIMELESS (rs2291738, rs1082214), and RORA (rs4774370, 
rs8027829, rs1568717, rs4774388) which associated with depression and disturbed 
sleep (Pointwise P<0.05) in the two previous studies (I and II). 
 
Marker selection (I-III)  
 
The selection of haplotype tagging SNPs was based on the Centre d’Etude du Poly-
morphisme Humain (CEPH) genotype data of the International HapMap Project 
(The International HapMap Consortium, 2005), using a tool Tagger implemented in 
Haploview program (V.4.0) (Barrett et al., 2005). The tagging SNPs were selected 
with a cut-off value for r2 of 0.8 and minor allele frequency of 0.2 (study I), or 0.1 
(study II). For the largest genes (NTRK2, NPAS2, and RORA), SNPs were selected 
evenly spaced throughout the gene with the same threshold values.  
 
 
 
4.4 Genotyping 
 
DNA extraction (I-III) 
 
Genomic DNA was extracted from ethylenediaminetetraacetic acid (EDTA)-treated 
peripheral blood leukocytes following the standard manufacturer’s protocol for the 
‘PureGene DNA isolation kit’ (Gentra Systems, Minneapolis, Minnesota, USA). 
DNA samples were stored at -70oC before they were used. 
 
Sequenom’s MassARRAY platform  
 
Genotyping of SNPs in the Health 2000 sample (studies I-III) was performed at the 
Finnish Genome Center in Helsinki using Sequenom’s MassARRAY with iPLEX 
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Gold and MALDI-TOF (matrix-assisted laser desorption-ionization-time of flight) 
mass spectrometry, following the manufacturer’s guidelines (Sequenom Inc., San 
Diego, CA, USA). Allele-specific primers for the SNP assays were designed using 
the Sequenom’s MassARRAY Assay Designer software (V.3.1) (Sequenom Inc., 
San Diego, CA, USA). As quality controls, eight duplicated DNA samples and eight 
water controls were included in each plate. The qualities of genotype spectra were 
analyzed using MassARRAY Spectro TYPER software (V.2.0 and 4.0), and verified 
manually. 
 
Repeat length polymorphisms and RFLP genotyping 
  
Repeat length polymorphisms from the SLC6A4 promoter region (5-HTTLPR), from 
intron 2 (STin2 VNTR), and from the promoter region of MAOA (MAO-A-30bp 
VNTR) were genotyped in study I. The PCR primers were designed with the Primer3 
program (Rozen and Skaletsky, 2000). SNP rs25531, located next to the 5-HTTLPR, 
was also genotyped using the MspI restriction enzyme on the 5-HTTLPR PCR prod-
uct, which resulted in the cutting of the long allele (L) into fragments of 150 and 99 
bp in case that the minor allele (G) of rs25531 was present in the sequence (Chorbov 
et al., 2007). The PCR products were electrophoresed on an ABI3730 DNA sequen-
cer (Applied Biosystems, Foster City, CA, USA) and the alleles automatically iden-
tified using an ABI GENEMAPPER (V.4.0) and then verified manually. 
 
Illumina 610 K platform 
 
Genotypes from the Genmets (D-) and FINRISK 2007 samples (studies II and III) 
were obtained from a GWAS dataset, which was originally genotyped by means of 
the Illumina 610K chip (Illumina HumanHap 610-Quad SNP array, San Diego, CA, 
USA) at the Wellcome Trust Sanger Institute, UK. 
 
Quality control 
 
For studies I and II the overall average genotyping success rate for the SNP data was 
≥ 95%. The Hardy-Weinberg equilibrium with a cut-off of P<0.05 was applied by 
using the Haploview program (V4.1) (Barrett et al., 2005). In studies I and II, ten 
SNPs failed the HWE test and were excluded from further analyses. When genotyp-
ing with the Illumina 610K platform (studies II and III), the call rate for both indi-
viduals and markers was >95%, while the markers with MAF <1% or HWE p<1x10-
6 were excluded. 
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4.5 Statistical analyses 
 
Association analyses  
 
In studies I and II, a single SNP association test was performed to compare the allele 
frequencies between cases and controls (dichotomous outcome variables) by using 
the chi-square test. In study II, a linear regression model was also used to analyze 
GSS (a quantitative variable). Age and status for metabolic disorder were used as 
covariates. To investigate the statistical power available for significantly associated 
variants in studies I and II, the power at α=0.05 was calculated using a web-based 
genetic power calculator (Purcell et al., 2003). In study III, association analysis to 
self-reported habitual sleep duration (a quantitative variable) was performed sepa-
rately in females and males using a linear regression model, applying age and meta-
bolic disorder status as covariates. A logistic regression model was then used to test 
the following groups: short sleep duration (≤ 6 hours) vs. midrange sleep duration 
(7-8 hours), and long sleep duration (≥ 9 hours) vs. midrange sleep duration (7-8 
hours). All analyses were conducted separately for females and males using the 
PLINK software package, web-based version 1.00 and 1.06 (Purcell et al., 2007).   
 
In case-control comparisons (studies I and II), the following groups were tested: (1) 
all depressed patients against all controls (D+ vs. D-), (2) depressed patients with 
early morning awakenings against controls without early morning awakenings 
(D+EMA+ vs. D-EMA-), and (3) depressed patients with fatigue against controls 
without fatigue (D+FAT+ vs. D-FAT-). In addition, three multiallelic markers were 
analyzed in study I. Two different approaches were used to analyze 5-HTTLPR: (1) 
the S allele and L allele analyzed separately (5-HTTLPR1), (2) grouping the S allele 
and L allele together (5-HTTLPR2), taking into account that the expression of the L 
allele is equivalent to that of the S allele (Hu et al., 2006). The intron 2 VNTR 
(STin2 VNTR) was analyzed by grouping the 9R and 10R repeat alleles together and 
comparing them to 12R (Fan and Sklar, 2005). For MAO-A-30 bp VNTR analysis, 
alleles were divided in two groups with high transcription activity allele (3.5 R and 
4R), and low transcriptional activity allele (3R and 5R) (Sabol et al., 1998).  
 
Descriptive analyses in studies I and II. After the initial analyses, variants that had 
given associations with pointwise P<0.05 were selected for more detailed analyses 
in order to test for differences in allele frequencies between the different groups of 
cases with depression, and with disturbed sleep using PLINK (Purcell et al., 2007). 
The following non-overlapping groups were examined: (1) D+EMA-FAT- (n=41 
females and 16 males), (2) D+EMA+FAT+ (n=94 females and 58 males), (3) 
D+EMA+FAT- (n=15 females and 3 males; owing to the small number of males we 
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did not examine their allelic frequencies), (4) D+EMA-FAT+ (n=91 females and 33 
males), and controls, D-EMA-FAT- (n=578 females and 481 males). 
 
Analysis of interaction. In study II, SNP-SNP interactions were examined for vari-
ants that gave the strongest evidence of association to depression with disturbed 
sleep. The interaction of gender with the best-associated SNPs was also explored 
using the logistic regression model with age as covariate.  
 
Corrections for multiple testing. Associations in studies I, II, and III were adjusted 
for controlling false-positive results by using the permutation and Bonferroni tests. 
Bonferroni correction is considered a strict method where a significance threshold 
(alpha=0.05) is divided by the number of all examined models. Therefore, in the 
primary analyses of studies I-III we used max (T) permutation test with 10,000 per-
mutations to obtain empirical corrected P-values. These analyses were conducted 
using the PLINK software package, web-based version 1.00 and 1.06 (Purcell et al., 
2007). The rationale behind the permutation test is that it preserves the LD structure 
between SNPs which provides a less stringent correction for multiple testing in 
comparison to the Bonferroni tests that assumes all tests are independent (Purcell et 
al., 2007). 
 
Linkage disequilibrium (LD) and haplotype-based association analyses  
 
LD between genotyped variants in the candidate genes was estimated using the 
Haploview program (V.4.0) (Barrett et al., 2005). The PLINK version 1.00 and 1.06 
was used for the association analyses of two-SNP (studies I-III), three-SNP (studies 
II and III), and four-SNP haplotypes (study II) with the sliding window approach 
(Purcell et al., 2007). SNPs giving an association of P<0.05 in the single SNP analy-
sis (studies I and II), and those which survived the multiple correction tests in study 
III, were included in the haplotype-based association test. 
 
 
 
Analysis of transcription factor binding sites 
 
Gender differences can be explained by several molecular and neurobiological 
mechanisms (see in section 2.1.4). The hormonal regulation of gene expression may 
play an important role in gender differences in depression and sleep (Dzaja et al., 
2005, Bangasser et al., 2010). Therefore, in studies II and III, the transcription factor 
binding sites of the selected genes were analyzed using the tool ConSite, a platform-
independent web resource (Sandelin et al., 2004). The orthologous pairs of genomic 
sequences were retrieved using a genome browser, EnsEMBL (www.ensembl.org), 
and the retrieved pairs of genomic sequences were re-aligned using the ORCA 
aligner (Sandelin et al., 2004). 
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5 RESULTS AND DISCUSSION 
5.1 Contribution of variation in candidate genes from seroton-
ergic and glutamatergic neurotransmission, neural plasticity 
and the HPA-axis to depression, and disturbed sleep 
 
A large majority of individuals who suffer from depression also have sleep difficul-
ties (Benca et al., 1997), and disturbed sleep has been characterized as one of the 
diagnostic criteria for depression (American Psychiatric Association, 2000). In fact, 
several symptoms related to sleep disturbances, including early morning awakenings 
and fatigue, are frequently found in patients with depression. Accordingly, we hy-
pothesized that the presence or absence of the symptoms and signs of sleep distur-
bance may also reflect differences in the neurobiological processes underlying de-
pressive disorders. Pathways of serotonergic and glutamatergic neurotransmission 
are primarily involved in the regulation of wakefulness and REM sleep (Andretic et 
al., 2008). Animal studies have shown that in many brain regions serotonin and 
glutamate are present at the highest levels during wakefulness and at the lowest 
during REM (Portas et al., 2000, Datta et al., 2001). Remarkably, REM sleep altera-
tions are typically observed in depression (Srinivasan et al., 2009). Furthermore, 
stressful life events can provoke HPA-axis disturbances that play a role in the etiol-
ogy of depression and induce sleep changes (Wang et al., 2008). Dysfunctioning of 
neural plasticity is linked to the pathophysiology of MDD and sleep problems 
(Pittenger and Duman, 2008). Therefore, in the aim of the present study was to ex-
amine the role of polymorphisms in such candidate genes, which are functionally 
related to the serotonergic and glutamatergic neurotransmission systems, to neural 
plasticity, and the HPA-axis, in the etiology of depression and disturbed sleep. As-
sociations for the allelic variants of 14 candidate genes was assessed using 78 mark-
ers in 384 depressed individuals and 1270 controls from the population-based Health 
2000 cohort (http://www.terveys2000.fi/indexe.html). The analyses were focused on 
patients with depression (D+) (n=259 females and 125 males), depressed patients 
with early morning awakenings (D+EMA+) (n=109 females and 61 males), and 
depressed patients with fatigue (D+FAT+) (n=194 females and 103 males). The 
association results of single SNP and haplotype-based analyses are presented in 
tables 14 and 15.  
 
Several variants of selected functional candidate genes were identified in this work, 
which could be among the genetic risk factors for depression. In addition, the ge-
netic background for depression without symptoms of disturbed sleep and depres-
sion with such symptoms was assessed. These findings show, for the first time, that 
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some of the genetic risk for depression may actually relate primarily to genetic risk 
of disturbed sleep, as shown for allelic variations of TPH2 in females. Others, such 
as CREB1 in males, do not show any specificity for sleep related symptoms in their 
genetic risk for depression. 
 
Amongst the genes that are involved in serotonergic neurotransmission, variants 
from TPH2, SLC6A4, COMT, and MAOA were studied. Rs12229394 from intron 8 
of TPH2 was associated with depression accompanied by fatigue in females 
(P=0.005, OR=1.40, associating allele ‘A’), as did the A-C haplotype of rs12229394 
and rs4760820 (P=0.003, OR=1.45). These two SNPs of TPH2 are tightly linked 
with each other (LD rs12229394/ rs4760820 D’=0.92, r2=0.228), as shown in figure 
9. The allele ‘A’ of rs12229394 was also found to associate with fatigue in the con-
trol group (D–) (P=0.049, OR=1.34). As signs of poor sleep are well-known risk 
factors for depression, this finding may reflect that genetic predisposition to fatigue 
increases the risk of depressive disorders later in life. Previous studies have found 
evidence for an association of variants from the exon 7 and intron 8 region of the 
TPH2 gene with suicide in MDD (Ke et al., 2006, Lopez de Lara et al., 2007), 
schizoaffective disorder, suicide attempt (Zhou et al., 2005), and with bipolar disor-
der (Lopez et al., 2007) (Figure 10). Thus, results by others and us support the prob-
ability of an involvement of 5’ regions of TPH2 in the regulation of mood (Figure 
10). 
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Table 14. Association results for genes from serotonergic and glutamatergic 
neurotransmission, neural plasticity, and the HPA-axis with depression and 
disturbed sleep in females and males. 
NP Alleles  D+ D+EMA+ D+FAT+ ┼MAF (D+) ┼MA
OR P- 
value 
OR P-
value 
OR P-
value 
EMA- 
FAT- 
EMA+ 
FAT+ 
EMA+ 
FAT- 
EMA- 
FAT+ 
EMA
FAT
 
4251417 C/T 1.49 0.025 1.31 0.323 1.46 0.050 0.10 0.10 0.03 0.12 0.07
12229394 G/A 1.28 0.023 1.34 0.059 1.40 0.005 0.32 0.36 0.43 0.38 0.30
s 
12185692 C/A 0.75 0.009 0.77 0.111 0.74 0.014 0.35 0.34 0.40 0.34 0.40
769407 G/C 1.22 0.071 1.41 0.023 1.33 0.025 0.26 0.39 0.20 0.31 0.28
687577 C/A 0.70 0.046 0.80 0.424 0.76 0.213 0.03 0.09 0.10 0.08 0.11
3848874 G/A 1.57 0.002 1.70 0.008 1.62 0.002 0.13 0.17 0.13 0.14 0.10
nes 
3738401 G/A 1.30 0.023 1.00 0.994 1.28 0.064 0.36 0.26 0.23 0.36 0.25
11904814 T/G 0.85 0.136 0.84 0.279 0.74 0.021 0.39 0.31 0.46 0.31 0.38
6265 C/T 0.79 0.123 0.70 0.136 0.66 0.027 0.15 0.08 0.30 0.11 0.15
1491850 T/C 0.76 0.015 0.84 0.306 0.79 0.066 0.37 0.40 0.36 0.33 0.43
173365 G/A 1.04 0.728 1.36 0.041 1.02 0.841 0.32 0.37 0.36 0.25 0.29
s 
504677 C/T 0.84 0.223 0.59 0.010 0.76 0.088 0.50 0.34 - 0.46 0.46
778330 A/G 1.38 0.045 1.37 0.144 1.43 0.040 0.30 0.26 - 0.20 0.19
nes 
11904814 T/G 0.58 0.0008 0.56 0.008 0.57 0.002 0.20 0.25 - 0.25 0.38
2709356 C/T 1.46 0.044 1.4 0.214 1.42 0.087 0.13 0.18 - 0.17 0.14
Chr: Chromosome. Alleles: Major/Minor. Bold face P-values show permutation-based 
P-values< 0.05 [Not Bonferoni-corrected P-values]. 
┼MAF in non-overlapping group of cases (D+) and controls (D-) based on the presence 
or absence of EMA or fatigue. 
D+EMA+FAT- allele frequencies were not examined in this group due to the small 
number of males (n=3).   
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Table 15. Haplotype-based association results given for the haplotype that gave the most 
significant P-values. 
Gene SNPs Haplotype Frequency 
in cases 
Frequency 
in  
controls 
OR P- 
values 
Phenotype Gender 
TPH2 rs12229394- 
rs4760820 
A-C 0.38 0.30 1.45 0.003 D+FAT+ Females 
GRIA3 rs3848874- 
rs687577 
A-C 0.15 0.10 1.54 0.001 D+FAT+ Females 
CREB1 rs11904814- 
rs10932201 
G-T 0.25 0.15 1.94 0.003 D+EMA+ Males 
 rs11904814- 
rs10932201 
G-T 0.25 0.16 1.73 0.001 D+FAT+ Males 
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Figure 9. Linkage disequilibrium structure of the TPH2 SNPs studied in the Health 
2000 subjects. The LD and haploblock structure of 9 SNPs of TPH2 in the study sub-
jects created with Haploview program (Barrett et al., 2005). SNPs are numbered 5’ to 3’ 
direction accordingly their relative location. Each square representing a pairwise com-
parison between two SNPs, LD (D’) is shown as different shadings of red darker color 
indicating higher values of D’, up to a maximum of 1. Thick black triangles represent 
haploblocks, i.e. regions of high LD, between the SNPs. Here blocks are defined using 
the algorithm solid spine, which identifies the blocks that the first and last SNPs in a 
block are in strong LD with all intermediate SNPs, but these in-between markers are not 
necessarily in LD with each other (Barrett et al., 2005). Block 1 includes markers from 
intron 2, intron 5, and exon 7. Block 2 is located within intron 8, the strongly associated 
marker, rs12229394, is located within this block. Block 3 includes markers from intron 8 
and exon 9.  
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Figure 10. Schematic presentation of the TPH2 gene. The 5’ promoter region (P), 12 
introns, and exons (grey blocks) are presented in their approximate locations. SNPs of 
the TPH2 gene, which were investigated in the present study, are highlighted with bold 
face. The figure also summarizes previous evidence for association in the TPH2 gene, 
the exon 7 and intron 8 part of the TPH2 gene is involved in the regulation of mood.  
No significant association with a 5-HTTLPR functional polymorphism in the pro-
moter region of the serotonin transporter gene (SLC6A4) was detected, which is 
consistent with other studies (Ohara et al., 1998, Serretti et al., 2002, Mendlewicz et 
al., 2004). An allelic variant of 5-HTTLPR may predispose to depression in indi-
viduals with stressful life events (McCaffery et al., 2006, Uher and McGuffin, 2008), 
but the present study lacked the examination of stressful life events. A trend for 
association of SLC6A4 with depression and depression accompanied by fatigue 
(P=0.025, 0.050, respectively) in females was seen for the SNP rs4251417 in intron 
1. A tendency of association was also observed with depression in females for the 
high-activity allele of MAOA-uVNTR (P=0.055, OR=0.80) and allele Met 108/158 from 
the functional SNP of COMT (P=0.068; OR=0.80). For all of the genes studied from 
the serotonergic system, associations were observed only with females, which may 
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relate to a variable regulation of gene expression in the two genders, as expression 
of serotonin transporter genes is modified by sex hormones (Gubbels Bupp et al., 
2008). 
 
Amongst the genes involved in glutamatergic neurotransmission, variants of GAD1, 
P2RX7, DAOA and GRIA3 were studied here. The intronic SNP rs3848874 of 
GRIA3 associated with depression, depression accompanied by early morning awak-
enings, and fatigue in females (P=0.002, 0.008 and 0.002, respectively). A major 
haplotype A-C of rs3848874 and rs687577 of GRIA3 was associated with depression 
in females (P=0.001, OR=1.54). GRIA3 has previously been identified in Italian 
populations among female patients with schizophrenia (Magri et al., 2008). For 
GAD1, rs12185692 in the promoter region showed evidence of association with 
depression and depression accompanied by fatigue (P=0.009, 0.014, respectively) in 
females. Previous studies suggested a role for the promoter region of GAD1 in bipo-
lar affective disorder (Lundorf et al., 2005), and in schizophrenia (Addington et al., 
2005). In addition, variants from other parts of GAD1 were associated with anxiety 
and depressive disorders (Hettema et al., 2006). In males, rs778330 from DAOA 
associated with depression and depression accompanied by fatigue (P=0.045, 
OR=1.38; P=0.040, OR=1.43, respectively), while rs504677 from the P2RX7 gene 
showed association with depression accompanied by early morning awakenings 
(P=0.010, OR=0.59).  
 
Amongst the genes with a function in neural plasticity, DISC1, CREB1, NTRK2, and 
BDNF were studied. Rs2709356 located in intron 1 of CREB1 showed association 
with depression in males (P=0.044, OR=1.46), as did allele ‘T’ of rs11904814 in 
intron 3 of CREB1 (P=0.0008, OR=0.58). The same allele associated significantly 
also with depression accompanied by fatigue in females (P=0.021, OR=0.74). Alle-
lic haplotype G-T of rs11904814 and rs10932201 associated with depression ac-
companied by early morning awakenings (P=0.003, OR=1.94) and with depression 
accompanied by fatigue (P=0.001, OR=1.73) in males. These three SNPs of CREB1 
were in the same LD block (LD rs2709356/rs10932201 D’=1.0, r2=0.144; 
rs2709356/rs11904814 D’=0.988, r2=0.091; rs10932201/rs11904814 D’=1.0, 
r2=0.518), as shown in figure 11. 
 
CREB1 is a member of the basic leucine zipper family of transcription factors con-
sisting of 341 amino acids (Mayr and Montminy, 2001). The promoter region of this 
gene has earlier been observed to be associated with depressive disorders in females 
(Zubenko et al., 2003), and in suicide (Perlis et al., 2007) (Figure 12). Furthermore, 
the CREB1 variant from intron 5 also associated with MDD (Dong et al., 2009) 
(Figure 12). The variant associated with suicide, rs7569963 (Perlis et al., 2007), is in 
LD with intron 3 SNP rs11904814 (D’=1, r2=0.892). Zubenko and Huges 3rd re-
ported that G to A transition at position -656 of the promoter region of CREB1 
changed the activity of the promoter in the presence of female gonadal steroids 
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(Zubenko and Hughes, 2009). Therefore, it is possible that this candidate gene of 
mood disorders can exert its effect differentially in males and females.  
 
Figure 11. Linkage disequilibrium structure of the CREB1 SNPs studied in the 
Health 2000 subjects. The LD and haploblock structure of 3 SNPs of CREB1 in the 
study subjects created with Haploview program (Barrett et al., 2005). Each square repre-
senting a pairwise comparison between two SNPs, dark red color indicates high value of 
D’, up to a maximum of 1. The thick black triangle represents a haploblock i.e. region of 
high LD between the SNPs. Block 1 includes markers from intron 3 of CREB1. 
 
RESULTS AND DISCUSSION 
 
THL — Research 81/2012 81 A Study of Candidate Genes in Depression and Disturbed Sleep 
 
 
Figure 12.  Schematic presentation of the CREB1 gene. The 5’ promoter region (P), 9 
introns, and exons (grey blocks) are presented in their approximate locations. SNPs 
studied from the CREB1 gene in the present thesis, are highlighted with bold face. The 
figure also summarizes previous evidence for association of the CREB1 gene with mood 
disorders. 
In addition, nominal evidence of association between rs3738401 at the 5’ end of 
DISC1 and depression in females was found (P=0.023, OR=1.30). The non-
synonymous SNP rs6265 on exon 2 of BDNF leads to an amino acid substitution 
from valine to methionine at codon 66 (Val66Met), which associates with a de-
creased distribution of BDNF in neuronal dendrites (Egan et al., 2003). In the pre-
sent study, a nominal association of allele ‘C’ (Val66) with depression accompanied 
by fatigue in females was observed (P=0.027; OR=0.66). Association studies have 
repeatedly found the involvement of BDNF polymorphism (Val66Met) in psychiat-
ric diseases. In other population-based studies, an association of the Val66 (Valine) 
allele with bipolar disorder and with MDD (and its related personality traits) was 
also observed (Neves-Pereira et al., 2002, Sklar et al., 2002, Sen et al., 2003, Green 
et al., 2006). Another variant of BDNF from promoter region, rs1491850, also 
showed nominal evidence of association with depression in females (P=0.015, 
OR=0.76). Furthermore, no significant evidence of association was observed for the 
NTRK2 gene, which is involved in neuronal development and long term memory 
formation, and supports the stress-induced deficits in the hippocampus which can be 
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noted in mood disorders (Pittenger and Duman, 2008). The NTRK2 gene has a com-
plex genomic organization, spanning 350 kb and containing multiple splicing iso-
forms within the 19 exons. Therefore, it is possible that there are no causative risk 
variants for depression and disturbed sleep in any of the SNPs tested, thus these 
variants remain to be found in NTRK2. 
 
Amongst the genes from the HPA-axis, nominal evidence of association for the 
intronic variant rs173365 of CRHR1 with depression accompanied by early morning 
awakenings in females was found (P=0.041, OR=1.36, associating allele ‘A’). The 
same allele has also been associated with adult depression arising from childhood 
abuse (Bradley et al., 2008), suggesting that dysregulation of the HPA-axis is one of 
the major neuroendocrine abnormalities in depression. 
 
In conclusion, these results support the involvement of candidate genes from sero-
tonergic, glutamatergic, neuralplasticity, and HPA-axis systems in the genetic back-
ground of depression and disturbed sleep. These results confirm the genetic hetero-
geneity of depression and provide evidence for partially separate genetic risk factors 
among males and females.  
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5.2 Systematic analyses of circadian genes reveals associa-
tion of TIMELESS with depression and disturbed sleep (II) 
 
The first study of this thesis revealed that gender-dependent and symptom-specific 
differences may be found in the genetic background of depression and disturbed 
sleep. The genetic variants which associate with depression also associate with fea-
tures of disturbed sleep, such as early morning awakenings and fatigue. In study II, 
this hypothesis was expanded to include genes from the circadian system that could 
be associated with depression and signs of disturbed sleep. Shortage of light may 
trigger the seasonal fluctuation which is common in a number of patients with mood 
disorder (Shin et al., 2005, Grimaldi et al., 2009), and mutations in circadian genes 
are linked with the metabolic syndrome (Turek, 2008). Therefore, whether the same 
genes of the circadian system would associate with seasonal variations in metabolic 
or mental functions was also examined. The associations of a total of 113 SNPs 
from 18 genes of the circadian system in 1654 subjects from the Health 2000 cohort 
were investigated. 
 
Statistically strongest evidence was found for allelic variants of the TIMELESS gene 
in both females and males. Of the four SNPs of TIMELESS examined, rs7486220 in 
the intron 1 region showed the strongest association with the minor allele ‘A’, which 
increases the risk for depression with fatigue (P=0.000099, OR=1.66) in females 
(Table 16). This finding survived the correction for multiple testing (Permutation-
based corrected empirical P=0.0056, Bonferroni corrected P=0.033). In males, the 
SNP rs1082214 in the promoter region associated with depression was accompanied 
by early morning awakenings (D+EMA+) with associating minor allele ‘T’ 
(P=0.0009, OR=2.7, Permutation-based corrected empirical P=0.0374, Bonferroni 
corrected P=0.22). In addition, this allele also associated to D-EMA+ in the second 
sample set in males (Genmets (D-) samples) (P=0.038, OR=1.52) and D-FAT+ 
(P=0.0016, OR=1.79). Thus, although the ‘T’ allele was associated with “depres-
sion-free” samples, this allele might increase the risk for symptoms of disturbed 
sleep like early morning awakenings and fatigue, and in this way it may also impact 
on risk for depressive disorder. 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
THL — Research 81/2012 84 A Study of Candidate Genes in Depression and Disturbed Sleep 
 
Table 16. The association results of genes from the circadian system with 
depression and disturbed sleep in females and males. 
SNP Alleles  D+ D+EMA+ D+FAT+ ┼MAF (D+) 
OR P- 
value 
OR P-
value 
OR P-value EMA- 
FAT- 
EMA+ 
FAT+ 
EMA+ 
FAT- 
EMA- 
FAT+ 
rs2291739 T/C 1.21 0.072 1.31 0.060 1.51 0.0004 0.3 0.47 0.3 0.44 
rs2291738 G/A 1.22 0.055 1.26 0.110 1.52 0.0005 0.37 0.46 0.33 0.47 
rs7486220 G/A 1.34 0.009 1.55 0.003 1.66 0.000099* 0.26 0.46 0.23 0.40 
rs1082214 C/T 0.60 0.030 0.33 0.012 0.66 0.126 0.03 0.02 0.03 0.06 
rs1982350 A/G 1.24 0.033 1.09 0.547 1.27 0.04 0.48 0.47 0.46 0.44 
rs969485 A/G 0.81 0.121 0.90 0.587 0.70 0.026 0.17 0.18 0.4 0.17 
rs4774370 T/C 0.75 0.045 0.85 0.449 0.78 0.122 0.11 0.18 0.16 0.17 
rs4774388 A/G 0.76 0.093 0.68 0.128 0.61 0.010 0.19 0.10 0.1 0.07 
rs1619450 T/C 0.64 0.022 0.76 0.316 0.59 0.017 0.08 0.09 0.06 0.05 
rs10991925 A/G 1.31 0.033 1.06 0.773 1.19 0.227 0.25 0.17 0.3 0.24 
rs135745 C/G 1.17 0.129 1.27 0.107 1.34 0.015 0.41 0.46 0.4 0.48 
rs10838524 A/G 1.24 0.038 1.45 0.010 1.22 0.104 0.48 0.45 0.3 0.49 
rs1082214 C/T 1.56 0.067 2.70 0.0009* 1.72 0.037 0.03 0.15 - 0.03 
rs4964060 G/A 0.79 0.138 0.73 0.143 0.68 0.028 0.4 0.36 - 0.34 
rs7304939 C/T 0.6 0.073 0.54 0.133 0.46 0.023 0.15 0.05 - 0.06 
rs2290036 T/C 1.70 0.010 1.88 0.014 1.57 0.041 0.2 0.16 - 0.12 
rs12712083 A/G 0.78 0.091 0.87 0.464 0.72 0.045 0.4 0.39 - 0.35 
rs2063690 C/G 1.37 0.165 1.72 0.059 1.71 0.037 0.03 0.13 - 0.09 
rs885747 C/G 1.04 0.787 0.66 0.040 0.93 0.705 0.4 0.40 - 0.45 
Chr: Chromosome. Alleles: Major/Minor. Bold face P-values stand for permutation-
based P-values< 0.05. *SNP survived multiple testing correction for association with 
D+FAT+ in females (rs7486220 Permutation-based corrected empirical P=0.0056, Bon-
ferroni corrected P=0.033), and with D+EMA+ in males (rs1082214 Permutation-based 
corrected empirical P=0.0374, Bonferroni corrected P=0.22). ┼MAF in non-overlapping 
group of cases (D+) and controls (D-) based on the presence or absence of EMA or fa-
tigue. D+EMA+FAT- allele frequencies were not examined in this group due to the 
small number of males (n=3).  
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Haplotype analyses showed allelic coherence of TIMELESS gene in the genetic 
background of depression and disturbed sleep (Figure 13A). The haplotype C-A-A-
C of rs1082214-rs2291738-rs7486220-rs2291739 of the TIMELESS gene showed 
strongest association with D+FAT+ (P=0.0000075, OR=1.72) in females, whereas 
the haplotype T-G-A-C associated with D+EMA+ (P=0.003, OR=2.61) in males. 
The haploblock and LD pattern of genotyped markers of TIMELESS gene is pre-
sented in (Figure 13B). 
 
A) 
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B)  
 
Figure 13. Schematic presentation of the TIMELESS gene. Figure 13 A) demon-
strates genomic structure and approximate positions of genotyped SNPs within the gene 
and its promoter region. SNP rs1082214 locates in the promoter region, SNP rs7486220 
locates in intron 1 region, SNP rs2291738 locates in intron 22, and SNP rs2291739 in 
exon 25. Figure 13 A shows 2-SNP, 3-SNP, 4-SNP haplotype association with D+FAT+ 
in females and D+EMA+ in males respectively. Figure 13 B) demonstrates the linkage 
disequilibrium between the TIMELESS SNPs studied in the present thesis. The LD and 
haploblock structure of 4 SNPs of TIMELESS created with Haploview program (Barrett 
et al., 2005). Each square representing a pairwise comparison between two SNPs, LD 
(D’) is shown as different shadings of red darker color indicating higher values of D’, up 
to a maximum of 1. The thick black triangles represent haploblocks, i.e. regions of high 
LD between the SNPs. Block 1 include markers from intron 22 and exon 25. Block 2 
includes markers from intron 1 and the promoter region. 
The major allele ‘C’ of rs1082214, which was part of the high-risk haplotype for 
depression with fatigue in females, also associated to mental factor of GSS (GSSf2) 
(seasonal variation in sleep duration, social activity, mood and energy level) 
(P=0.016, β=-0.110). Furthermore, females from “depression-free” (Genmets (D-)) 
samples showed an association with minor allele ‘T’ of rs1082214 (P=0.036, 
β=0.123). Thus, major allele ‘C’ of rs1082214 is involved in the development of 
seasonal changes in mood.   
 
Earlier studies have indicated evidence for association between SNPs at the cir-
cadian gene loci and bipolar disorder, schizophrenia, (Mansour et al., 2006), insom-
nia, and mania (Shi et al., 2008). The major allele ‘G’ of the SNP rs2291738, lo-
cated in intron 22, was shown here to be associated with D+FAT+ (P=0.0005, 
OR=1.52) in females, and to be one of the alleles which associated with bipolar 
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disorder patients (Mansour et al., 2006). These results thus confirm the involvement 
of TIMELESS with susceptibility to mood disorder. 
 
TIMELESS is involved in cell survival after DNA damage (Unsal-Kacmaz et al., 
2005), and is an essential component in the regulation of the circadian rhythm. It 
interacts with PER proteins in the cytoplasm and forms a heterodimer complex, thus 
allowing their entry into the nucleus, where they inhibit the ARNTL-CLOCK and 
ARNTL-NPAS2 complexes, which induce the transactivation of PER1 (Sangoram et 
al., 1998). Therefore, an interaction analysis of other circadian gene variants with 
the TIMELESS variants was performed here. Evidence was found for interaction 
between TIMELESS rs7486220 and rs3027188 of PER1 in females with D+FAT+ 
(P=0.008, OR=0.45). In addition, there was evidence in males with D+EMA+ of 
interaction between rs2291739 of TIMELESS and rs1868049 of ARNTL (P=0.0006, 
OR=4.36), rs7486220 of TIMELESS and rs4774370 of RORA (P=0.003, OR=3.12), 
and rs1082214 of TIMELESS and rs2269457 of NR1D1 (P=0.003, OR=3.97). These 
findings on interaction may point to a genetic network that controls elements of the 
circadian system, which are also involved in the regulation of sleep and mood. Fur-
ther, there was evidence for interaction of gender with rs7486220 or rs1082214 to 
D+EMA+ (P=0.0015 and 0.000023, respectively), and D+FAT+ (P=0.005 for both 
variants). In addition to TIMELESS, polymorphisms from ARNTL, CRY2, RORA, 
NFIL3, CSNK1E, ARNTL2, NPAS2, TIPIN, and PER1 indicated associations with 
depression and sleep-related problems (Table 16), but these findings do not stand up 
to correction for multiple testing. 
 
The biocomputational analysis for transcription factor binding sites performed here 
showed a binding site for a chicken ovalbumin upstream promoter transcription 
factor (COUP-TF) on 3017 bp from the 5’ upstream region of TIMELESS. COUP-
TF is a nuclear receptor and classified as a member of the steroid receptor family, 
which plays a role in mitigating estrogen-responsive gene expression (Wang et al., 
1989, Klinge, 1999). This could relate to a differential regulation of gene expression 
in males and females, and also to these findings of different susceptibility alleles for 
the two genders.  
 
Thus, the results in study II indicate involvement of TIMELESS in the etiology of 
depression and disturbed sleep and provide evidence for the gender-dependent and 
symptom-specific differences in the genetic background of depression and disturbed 
sleep. 
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5.3 Analyses of shared genetic background behind the regula-
tion of depressive disorder and sleep (III) 
 
In the first two studies of this thesis, variants from a number of candidate genes such 
as, TPH2, GAD1, GRIA3, BDNF, CRHR1, and TIMELESS were observed to be 
associated with depression and disturbed sleep. These findings suggest that insuffi-
cient or disturbed sleep is a precipitating factor in the initiation of depression in 
those individuals who also have a genetic vulnerability for depression. Moreover, 
results from studies I and II suggest that the same genetic factors that regulate mood 
also regulate features of sleep. Our previous study on 18,631 Finnish twins of same 
sex demonstrated that sleeping less than 7 hours per night increased the incidence of 
depressed mood 1.7 fold (Paunio et al., 2009). Therefore, a shared genetic back-
ground for the regulation of mood and sleep was hypothesized in study III. Conse-
quently, 23 SNPs were selected from 12 candidate genes that had shown evidence of 
association (P<0.05) with depression and disturbed sleep in studies I and II, and 
their association with sleep duration was assessed in 3147 healthy individuals from 
the population-based Health 2000 and FINRISK 2007 study samples. 
 
In the single marker association analyses, six SNPs showed nominal association (P< 
0.05), and rs687577 within intron 12 of GRIA3 located on the Xq25 was the only 
variant that associated with sleep duration in females (P=0.00001, permutation-
based corrected empirical P=0.00001, β=0.27; Bonferroni corrected P=0.0052; 
f=0.11) (Table 17). The association appears to be between the minor allele of GRIA3 
variant rs687577 (allele A) and long sleep in females (P=0.00001, permutation-
based corrected empirical P=0.0003, OR=1.89; Bonferroni corrected P=0.039, 
f=0.18) (Table 17). The association was significant in all three subsamples (Health 
2000, Healthy sleepers sample: permutation-based corrected empirical P=0.002 and 
β=0.24, Health 2000, Genmets (D-) sample: permutation-based corrected empirical 
P=0.004 and β=0.30; FINRISK 2007 sample: permutation-based corrected empirical 
P=0.04 and β=0.31).  
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Table 17. Single marker association results of sleep duration as well as short and long 
sleep in females (N=1626) and males (N=1521) from the population-based Health 2000 
and FINRISK study 2007 samples. 
Chr Gene  SNPs Alleles β /OR P- 
values 
Phenotype Gender 
12 TIMELESS rs2291738 G/A 1.22 0.048 Short sleep Males 
12 TIMELESS rs1082214 C/T 1.61 0.026 Long sleep Males 
12 TPH2 rs12229394 G/A 1.28 
1.33 
0.024 
0.041 
Short sleep 
Long sleep 
Males 
15 RORA rs4774388 A/G 1.42 0.010 Short sleep Males 
15 RORA rs4774370 T/C 0.72 0.037 Short sleep Females 
17 SLC6A4 rs4251417 G/A 0.15 0.027 Sleep  
duration 
Females  
X GRIA3 rs687577 C/A 0.27 
 
0.00001* Sleep  
duration 
Females 
X GRIA3 rs687577 C/A 1.89 0.00001* Long sleep Females 
Chr: Chromosome. Alleles: Major/Minor. *Bold face P-values showed permutation-based 
corrected and Bonferoni corrected P-values< 0.05, and non-bold P-values showed suggestive 
association (P< 0.05).  
Furthermore, a two-SNP haplotype association in intron 12 of GRIA3 gene revealed 
a protective haplotype for depression G-A of rs3848874 and rs687577 (study I), 
which was found to associate with longer sleep duration (P=0.0011, β=0.24). The 
distribution of rs687577 genotypes (C/C major/major; C/A major/minor; A/A mi-
nor/minor) also differed significantly in relation to sleep duration in females (Figure 
14, Table 18).  
  
RESULTS AND DISCUSSION 
 
THL — Research 81/2012 90 A Study of Candidate Genes in Depression and Disturbed Sleep 
 
                  
 
Figure 14. Hours of sleep in females in respect to their genotype at rs687577 from 
GRIA3 [ Adapted from (Utge et al., 2011)]. 
Table 18. Genotypes at rs687577 from GRIA3 in groups of female subjects showing 
different sleep lengths [Adapted from (Utge et al., 2011)]. 
Hours 
of 
sleep 
MAJOR/MAJOR (C/C) 
 
MAJOR/MINOR (C/A) or 
MINOR/MINOR (A/A) 
 
 Number 
of  
subjects 
Age 
(Average±SD) 
Frequency 
of C/C 
Number 
of 
 subjects 
Age 
(Average±SD) 
Frequency 
of C/A or 
A/A 
≤5 29 58.65±11.38 85% 5 60.2±14.72  15% 
 6 132 53±14.66 82% 29 52.34±16.02 18% 
7 450 50.37±12.70 81% 107 47.48±14 19% 
8 507 49.66±12.81 77% 150 47.38±13.48 23% 
9 114 46.51±16.14 68% 54 44.68±16.40 32% 
10 24 52.41±18.68 67% 12 48.75±13.53 33% 
≥11 2 45±12.72 29% 5 46.6±15.59 71% 
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Females who slept for 8 hours or less were more often homozygous (C/C) for the 
major allele, and a systematic decrease was seen in the proportion of C/C genotype 
carriers per hour of increase in sleep duration. The results were significant for C/C 
genotypes even when the group of extreme long-sleepers was excluded (permuta-
tion-based corrected empirical P=0.0002, β=0.21). The difference in average sleep 
duration for C/C genotypes, as compared to C/A or A/A, was observed in all age 
groups of females younger than 70 years (Figure 15, Table 19). In the previous study 
(study I), the results showed that major allele ‘C’ of rs687577 of GRIA3 was associ-
ated with depression (P=0.046, OR=0.70) (Table 14) in females, and here the fre-
quency of this allele was higher in the healthy females with short sleep duration, 
whereas minor allele ‘A’ was highly present in the healthy females with longer sleep 
duration. 
 
 
 
Figure 15. Sleep duration in different age groups of females in respect to their 
genotype at rs687577 from GRIA3 [Adapted from (Utge et al., 2011)].  
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Table 19. Number of female subjects in each age group [Adapted from (Utge et al., 
2011)]. 
Age 
groups 
MAJOR/MAJOR (C/C) 
 
MAJOR/MINOR (C/A) or 
MINOR/MINOR (A/A) 
 
 Number of  
subjects 
Sleep duration 
(Average±SD) 
Number of 
 subjects 
Sleep duration 
 (Average±SD) 
25-30 23 8±1.04 15 8.33±1.17 
31-40 268 7.74±0.87 94 7.89±1.22 
41-50 338 7.46±0.88 92 7.79±0.84 
51-60 302 7.35±0.96 80 7.68±1.38 
61-70 235 7.4±1.04 61 7.68±1.28 
71-75 80 7.45±1.13 13 7.46±1.33 
 
The associated region in GRIA3 was found within intron 12, towards the 3’end of 
the gene. Previous evidence of association of GRIA3 with various psychiatric disor-
ders has been identified at the 5’ end of the gene (Figure 16). Thus, the results re-
ported here support the probability of an involvement of the 3’ region of GRIA3 in 
the regulation of sleep duration (Figure 16). In order to further explore the mecha-
nisms for gender-specific association, a transcription factor analysis of GRIA3 was 
performed. A binding site for GATA-3 (GATA binding protein 3) was found at the 
promoter region of the gene (Figure 16): GATA-3 is a transcription factor with an 
important role in cellular development and, interestingly, containing one estrogen 
receptor (ERα) binding site near the 3’end (Usui et al., 2006, Carroll et al., 2006).  
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Figure 16. Schematic presentation of the GRIA3 gene [Figure modified from (Utge 
et al., 2011)]. The 5’promoter region (P), 15 introns, and 16 exons (grey blocks) are 
presented in their approximate locations. The bold SNPs indicate those variants that 
were included in the study, and the core haplotypes that gave evidence for association 
with sleep duration. A bent arrow indicates the transcription factor-binding site for 
GATA-3, 10 kb upstream (at 122135839 bp) from promoter start (at 122145839 bp). The 
figure also summarizes previous evidence of association of GRIA3 with mental retarda-
tion and bipolar disorder in females (Gecz et al., 1999), mental retardation in males 
(Chiyonobu et al., 2007), schizophrenia, mental retardation and autism (Guilmatre et al., 
2009), schizophrenia in females (Magri et al., 2008), sexual dysfunction during major 
depressive disorder (Perlis et al., 2009), and suicidal ideation emerging during citalo-
pram treatment of major depression (Laje et al., 2007, Laje et al., 2009).  
In conclusion, an association of the rs687577 variant from GRIA3 with sleep dura-
tion in females was revealed. The same allelic variant of the GRIA3 gene, which 
increases the risk for depressive disorders, was also found more often in healthy 
females with short sleep. The finding points to a shared genetic background in the 
regulation of sleep and mood as far as involving the mechanism of glutamatergic 
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neurotransmission, which is, in addition, playing an important role in the induction 
or maintenance of wakefulness (Manfridi et al., 1999, Wigren et al., 2007).  
 
 
5.4 Limitations of the studies I-III 
 
Despite these promising results of candidate genes involvement in depression and 
disturbed sleep, caution must be taken when drawing conclusions. First, the number 
of individuals with a depression diagnosis was limited and results need to be repli-
cated in other samples and populations. The sample size in studies I and II were 
small and underpowered to detect associations for variants that increase genetic risk 
(<1.5 in females and <1.8 in males). The hospital-based MDD cohort study, with 
prevalence of 0.06 (the average across sexes), also presented that a case-control 
study of MDD requires a sample size approximately 1.8 times greater (McGuffin et 
al., 1996). Second, in study I, none of the findings would remain significant if we 
would subject them to all of the analyses performed. It is noteworthy, however, that 
detected association with TIMELESS (study II) and GRIA3 (study III) variants sus-
tained after correction for multiple testing. Third, in the present thesis, individuals 
without information on stress were studied. Therefore, the effect of stressful life 
events was not studied, although the role of stress in the induction of sleep distur-
bances or depression is well known. Fourth, in study III, the data on self-reported 
sleep duration lacks information on possible naps during the day, which could have 
effect on duration of nighttime sleep, as this was not asked in the Health 2000 and 
FINNRISK 2007 study surveys. Therefore, future studies with prospective data 
collection would require a more detailed and comprehensive characterization of 
sleep regulation and the etiology of depression. 
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
Depression is a complex multifactorial disorder which relates to a number of genetic 
and environmental factors. Earlier studies of depression have provided evidence for 
an imbalance in neurotransmission in various regions of the brain; however, the 
precise mechanisms as well as the molecular etiology of depression are as yet 
largely unknown. Further investigation is needed to identify relevant factors that 
trigger the onset of the disorder. Most of the patients with major depression have 
deranged sleep patterns, leading to symptoms such as decreased or increased total 
sleep, frequent nocturnal awakenings, difficulties falling asleep, early morning 
awakenings, and fatigue. Evidence from previous epidemiological and twin studies 
has suggested that the regulation mechanisms of mood and sleep are genetically at 
least partially linked. 
 
In the present thesis, genetic liability factors which would increase the risk of de-
pression were sought by dividing the patients into categories redefined by the pres-
ence or absence of symptoms of insomnia, such as early morning awakenings and 
fatigue. Genetic variations were examined in functionally relevant candidate genes 
from serotonergic and glutamatergic neurotransmission, neural plasticity, the HPA-
axis, and the circadian system. Many of the polymorphisms from genes from these 
systems were found that may have a role in the etiology of depression and disturbed 
sleep. The findings also imply that some of the genetic factors which increase a 
liability to depression may also influence disturbed sleep. Some of the candidate 
genes, for example TPH2, GAD1 or CRHR1 in females, displayed an association 
with depression when the disorder was accompanied by symptoms of disturbed 
sleep, while other genes, such as CREB1 in males, associated with depression re-
gardless of the absence or presence of symptoms of disturbed sleep. This systemati-
cal analysis of genes from the circadian system revealed an association of the 
TIMELESS gene to depression with presence of early morning awakenings and fa-
tigue. In females, an association was observed between the same allelic variants of 
TIMELESS, and depression, accompanying fatigue and seasonal fluctuation of mood; 
while in males another allelic form of the gene showed an increased risk for depres-
sion with early morning awakenings. Hence, genetic abnormalities in the circadian 
clockwork have a potentially great impact on an individual’s health. These results 
also support the heterogeneity of depressive disorder in both a symptom and a gen-
der-specific manner. An allelic variant of GRIA3 was also identified to associate 
both with depressive disorder in females and short sleep duration in healthy females 
in independent population-based samples. Thus, some of the genetic mechanisms 
underlying the regulation of sleep duration also contribute to a risk of depressive 
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disorder. Consequently, these results provide evidence of a shared genetic back-
ground of sleep and mood.   
 
Identification of genetic variants which predispose to depression and disturbed sleep 
encourage several avenues for future work. In this thesis, a hypothesis driven candi-
date gene approach was used. The studied genes were selected due to their role in 
the pathophysiology of disease and previous evidence connecting them with the 
regulation of mood. However, when designing a study for heritable disorders, rela-
tively large sample sizes are needed to gain power to detect common variants of 
smaller effect. The genetic studies have now entered in a new era of genome-wide 
association studies (GWAS). The key feature of the success of GWAS has been its 
feasibility to examine large numbers of unrelated individuals by data on 500,000 to 
1,000,000 SNPs across the human genome (Raizen and Wu, 2011). Those analyses 
enable a hypothesis-free search for potential new susceptibility genes. However, due 
to the high number of statistical tests performed, association is considered signifi-
cant only with nominal P values of 10-8 and with replication of findings in independ-
ent cohorts, in order to exclude false-positive results (Sullivan et al., 2009). GWAS 
is best suited to reveal common genetic variants with small effects for complex ge-
netic disorders. The largest GWAS for MDD to date, the MDD2000+ study, com-
prised 2431 cases and 3673 screened controls (Wray et al., 2010). It is, however, 
estimated that sample sizes 1.8- to 2.4-fold greater would be needed for association 
studies of MDD (Wray et al., 2010). To date, very few GWAS have a targeted ge-
netic basis of sleep disorders. One example is restless legs syndrome (RLS) 
(Stefansson et al., 2007, Winkelmann et al., 2007, Winkelmann et al., 2011). 
Clearly many more studies using this approach are needed to study both sleep prob-
lems, and those related to depression. 
 
GWAS conducted on complex genetic disorders such as schizophrenia have re-
vealed that the genetic component of those diseases also comprises rare variants 
with large effects, missed by GWAS (Manolio et al., 2009, Cirulli and Goldstein, 
2010). Therefore, future studies will be required to identify rare variants with larger 
effects. Sequencing all the coding region of the genome (exome) and scanning the 
mutations that has changed sequence of protein, or sequencing the entire human 
genome, by using next generation-sequencing technology will help for identification 
of rare genetic variants and mutations causing human diseases (Ng et al., 2010). 
Furthermore, sleep is conserved in many model organisms, such as flies, fish, and 
mice, which could be used for studies focusing on function of the candidate genes 
revealed by genomic association studies. Thus, combining signals from functional 
genetic studies in animal models with association studies in humans may lead to a 
better understanding of mechanisms underlying disease pathogenesis. 
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Given all of the above, while the search for causal genetic variants to diseases con-
tinues, there is also increasing interest in pharmacogenetics. Such studies have, for 
example, provided information about how antidepressants act differently for people 
with different genetic backgrounds (Holsboer, 2008). Eventually, advances in under-
standing the genetic risk and identifying actual disease-predisposing variants will 
pave the way toward better strategies for treating depression and sleep problems. 
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8 ELECTRONIC DATABASE 
Databases and program 
 
ABI GENEMAPPER (V.4.0) 
(http://mvz.berkeley.edu/egl/resources/manuals/GeneMapper_Troubleshooting4.0_.
pdf) (Applied Biosystems, Foster City, CA, USA) 
 
ConSite, a platform-independent web resource (http://asp.ii.uib.no:8090/cgi-
bin/CONSITE/consite/) (Sandelin et al., 2004) 
 
dbSNP (http://www.ncbi.nlm.nih.gov/snp) (Sherry et al., 2001) 
 
FINRISK study 2007 survey (http://www.ktl.fi/portal/4168) (Peltonen et al., 2008) 
 
Genome browser, EnsEMBL (www.ensembl.org) 
 
HapMap (http://hapmap.ncbi.nlm.nih.gov/)  (The International HapMap Consortium, 
2003) 
 
Haploview program (V.4.0) (http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-
genetics/haploview/haploview) (Barrett et al., 2005) 
 
Health 2000 survey (http://www.terveys2000.fi/indexe.html) (Aromaa and Koskinen, 
2004) 
 
MassARRAY Spectro TYPER software (V.2.0 and 4.0) (http://www.sequenom.com) 
(Sequenom Inc., San Diego, CA, USA) 
 
PLINK software package, web-based version 1.00 and 1.06 
(http://pngu.mgh.harvard.edu/~purcell/plink/) (Purcell et al., 2007) 
 
Sequenom’s MassARRAY Assay Designer software (V.3.1) (http://cancer-
seqbase.uchicago.edu/documents/AssayDesign3.1Guide.pdf) (Sequenom Inc., San 
Diego, CA, USA) 
 
The Human Genome Project (HGP) (www.ornl.gov/hgmis) (Site sponsored by the 
U.S. Department of Energy Office of Science, Office of Biological and Environ-
mental Research, Human Genome Program) 
ELECTRONIC DATABASE 
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The 1000 Genomes Project (http://www.1000genomes.org) (Durbin et al., 2010) 
 
 
Literature search database 
 
Google scholar (http://scholar.google.com/) 
    
US National Library of Medicine National Institutes of Health 
(http://www.ncbi.nlm.nih.gov/pubmed/) 
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